Neuroactive steroids, compositions, and uses thereof
24(S)-hydroxycholesterol and related compounds are used to modulate NMDA receptors, addressing glutamatergic transmission imbalances in psychiatric disorders by enhancing or inhibiting its metabolism, improving treatment efficacy for conditions like schizophrenia and depression.
Patent Information
- Application Number
- JP2024137715
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-03-13
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for psychiatric disorders related to glutamatergic transmission imbalances lack effective modulators that can positively or negatively regulate NMDA receptors to address both reduced and pathologically increased transmission.
The use of 24(S)-hydroxycholesterol or structurally related sterols as positive or negative allosteric modulators of NMDA receptors, administered through compounds that enhance or inhibit enzymes involved in its metabolism, to regulate brain excitability and treat disorders such as schizophrenia, depression, and other CNS-related conditions.
This approach provides a targeted method for modulating NMDA receptor activity, potentially improving treatment outcomes for various psychiatric and neurological disorders by enhancing or reducing the endogenous activity of 24(S)-hydroxycholesterol, thereby addressing both hypo- and hyper-glutamatergic transmission.
Smart Images

Figure 2024159822000001 
Figure 2024159822000002 
Figure 2024159822000003
Abstract
Description
[Technical Field]
[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61 / 780,671, filed March 13, 2013, which is incorporated herein by reference. [Background technology]
[0002] Background of the Invention Brain excitability, defined as the level of an animal's arousal on a continuum ranging from coma to seizures, is controlled by various neurotransmitters. Generally, neurotransmitters are involved in controlling the conductance of ions across neuronal membranes. At rest, neuronal membranes have a potential (or membrane voltage) of approximately -70 mV, meaning the cell interior is negative relative to the cell exterior. This potential (voltage) is the result of the balance of ions (K+, Na+, Cl-, and organic anions) across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released as a result of neuronal action potentials. Upon release into the synaptic cleft, excitatory chemical messengers such as acetylcholine cause membrane depolarization (a change in potential from -70 mV to -50 mV). This effect is mediated by postsynaptic nicotinic receptors, which, when stimulated by acetylcholine, increase membrane permeability to Na+ ions. A decrease in membrane potential increases the probability of generating a postsynaptic action potential, which increases neuronal excitability.
[0003] NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission. Activation of these receptors contributes to synaptic plasticity in some contexts and to excitotoxicity in others. These receptors are ligand-gated ion channels that allow Ca2+ to pass through after binding of the neurotransmitters glutamate and glycine, and are essential for excitatory neurotransmission and normal CNS function. NMDA receptors are heteromeric complexes containing NR1, NR2, and / or NR3 subunits and possess distinct recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine and glutamate agonists and modulators. Positive modulators may be useful as therapeutic agents with potential clinical uses as nootropics and in the treatment of psychiatric disorders in which glutamatergic transmission is reduced or defective (see, for example, Horak et al., J. of Neuroscience, 2004, 24(46), 10318-10325). In contrast, negative modulators may be useful as therapeutic agents with potential clinical uses in the treatment of psychiatric disorders in which glutamatergic transmission is pathologically increased (e.g., treatment-resistant depression).
[0004] Neuroactive steroids such as pregnenolone sulfate (PS) have been shown to exert direct modulatory effects on several types of neurotransmitter receptors (e.g., GABAA receptors, glycine receptors, AMPA receptors, kainate receptors, and NMDA receptors). NMDA receptors are positively regulated by PS; however, the degree of modulation varies considerably, depending, for example, on the subunit composition of the receptor. In addition to PS, several other 3β-hydroxysteroids have been shown to potentiate NMDA receptors (see, e.g., Paul et al., J. Pharm. and Exp. Ther. 1994, 271, 677-682; Madau et al., Program No. 613.2 / B87. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009; Connick et al., Program No. 613.1 / B86. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009; Paul et al., J. Neurosci. 2013, 33, 17290-17300). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Horak et al., J. of Neuroscience, 2004, 24(46), 10318-10325 [Non-patent document 2] Paul et al., J. Pharm. and Exp. Ther. 1994, 271, 677-682 [Non-patent document 3] Madau et al., Program No.613.2 / B87.2009 Neuroscience Meeting Planner.Chicago,IL:Society for Neuroscience,2009 [Non-patent document 4] Connick et al., Program No. 613.1 / B86.2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009 [Non-patent document 5] Paul et al., J.Neurosci.2013,33,17290-17300 Summary of the Invention [Means for solving the problem]
[0006] Summary of the Invention Specifically described herein is a method for evaluating or treating a patient, for example, a patient with the disorders described herein, which method comprises: a) optionally obtaining a patient sample; b) obtaining and / or evaluating the sample for changes in the level of 24(S)-hydroxycholesterol compared with a control.In certain embodiments, the method further comprises administering to the patient an effective amount of 24(S)-hydroxycholesterol or structurally related sterols or steroids, oxysterols, NMDAR agonists or NMDAR positive allosteric modulators (PAMs), or compounds described herein, such as the compound of formula (I).In certain embodiments, the method further comprises administering to the patient an effective amount of NMDAR antagonists or NMDAR negative allosteric modulators (NAMs), or compounds described herein, such as the compound of formula (I). In some embodiments, the method further comprises administering to the subject a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., a compound that inhibits 24-hydroxycholesterol 7alpha-hydroxylase (CYP39)). In some embodiments, the method further comprises administering to the patient a compound that decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)).
[0007] In certain embodiments, 24(S)-hydroxycholesterol, structurally related sterols or steroids, or oxysterols are naturally occurring compounds (e.g., compounds naturally occurring in the brain of a subject), such as naturally occurring sterols or steroids. In some embodiments, the method includes administering 24(S)-hydroxycholesterol to a subject. In some embodiments, the method includes administering to a subject a compound described herein, such as a compound of Formula (I). In certain embodiments, the method includes administering to a patient an effective amount of an NMDAR antagonist or an NMDAR negative allosteric modulator (NAM), or a compound described herein, such as a compound of Formula (I). In some embodiments, the method includes administering to a subject a compound that enhances (e.g., increases) the endogenous activity or endogenous amount of 24(S)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(S)-hydroxycholesterol, such as a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)). In some embodiments, the method further includes administering to the patient a compound that decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)).
[0008] In some embodiments, 24(S)-hydroxycholesterol is compared with a reference standard, wherein the reference standard is a standard previously obtained from the patient.In some embodiments, the reference standard is an external reference standard that is not related to patient samples (for example, a universal standard or a standard from treatment and / or diagnostic guidelines).In some embodiments, when the level of 24(S)-hydroxycholesterol is reduced compared to the reference standard, the method indicates that the patient is a suitable candidate for treatment with 24(S)-hydroxycholesterol or structurally related sterols or steroids, oxysterols, NMDAR agonists or NMDAR positive allosteric modulators (PAMs), a compound that enhances (e.g., increases) the endogenous activity or endogenous amount of 24(S)-hydroxycholesterol (e.g., a compound that inhibits the enzyme that metabolizes 24(S)-hydroxycholesterol, for example, a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or a compound described herein, such as a compound of formula (I). In certain embodiments, when the level of 24(S)-hydroxycholesterol is elevated compared to a control baseline, the method suggests that the patient is a suitable candidate for treatment with an NMDAR antagonist, an NMDAR negative allosteric modulator (NAM), or a compound that reduces the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)).In certain embodiments, the method further comprises administering to the patient an effective amount of 24(S)-hydroxycholesterol or a structurally related sterol or steroid, an oxysterol, an agonist of NMDAR or a positive allosteric modulator (PAM) of NMDAR, a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or a compound described herein, such as a compound of Formula (I). In certain embodiments, the method further comprises refraining from treating the patient with 24(S)-hydroxycholesterol or a structurally related sterol or steroid, an oxysterol, an agonist of NMDAR or a positive allosteric modulator (PAM) of NMDAR, a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or a compound described herein, such as a compound of Formula (I). In certain embodiments, the method further includes administering to the patient an effective amount of an NMDAR antagonist or NMDAR negative allosteric modulator (NAM), a compound that reduces the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)), or a compound described herein, such as a compound of Formula (I).
[0009] In some embodiments, if the level of 24(S)-hydroxycholesterol is elevated compared to a control standard or decreased compared to a control standard, the patient is further evaluated for a mutation or polymorphism in a biosynthetic enzyme involved in the synthesis or metabolism of 24(S)-hydroxycholesterol. In some embodiments, if the level of 24(S)-hydroxycholesterol is elevated compared to a control standard or decreased compared to a control standard, the patient is determined to have a mutation or polymorphism in a biosynthetic enzyme involved in the synthesis or metabolism of 24(S)-hydroxycholesterol.
[0010] In certain embodiments, the level of 24(S)-hydroxycholesterol is measured by assessing the level of 24(S)-hydroxycholesterol or its fragments or metabolites in a subject. In certain embodiments, the level of 24(S)-hydroxycholesterol is measured by chromatographic (e.g., HPLC), spectroscopic (e.g., MS), or nuclear magnetic resonance (NMR) methods.
[0011] In certain embodiments, patient sample is body fluid sample, for example, blood sample.In certain embodiments, patient sample is biopsy material, for example, brain biopsy material, isolated specimen or surgical specimen.In certain embodiments, patient sample is obtained before administering treatment.In certain embodiments, the first treatment is administered before patient evaluation and / or before administering 24(S)-hydroxycholesterol or structurally related sterol or steroid, oxysterol, NMDAR agonist or NMDAR positive allosteric modulator (PAM), compound that enhances (for example, increases) the endogenous activity or endogenous amount of 24(S)-hydroxycholesterol (for example, compound that inhibits the enzyme that metabolizes 24(S)-hydroxycholesterol, for example, compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or compound described herein, such as compound of formula (I). In certain embodiments, the patient sample is obtained after administration of a treatment other than administration of 24(S)-hydroxycholesterol or a structurally related sterol or steroid, an oxysterol, an agonist of NMDAR or a positive allosteric modulator (PAM) of NMDAR, a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or a compound described herein, such as a compound of Formula (I). In certain embodiments, the first treatment is administered prior to evaluation of the patient and / or prior to administration of an NMDAR antagonist or NMDAR negative allosteric modulator (NAM), a compound that reduces the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)), or a compound described herein, such as a compound of Formula (I).In certain embodiments, the patient sample is obtained after administration of a treatment other than an NMDAR antagonist or NMDAR negative allosteric modulator (NAM), a compound that decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)), or a compound described herein, such as a compound of Formula (I).
[0012] In one aspect, the present specification also describes a kit or product that comprises multiple agents that can interact with 24(S)-hydroxycholesterol.In certain embodiments, the agent is NMDAR or NMDA.In some embodiments, the agent is / comprises a label such as a radioactive label or a fluorescent label.In some embodiments, the agent is a probe that interacts with 24(S)-hydroxycholesterol.
[0013] In certain embodiments, 24(S)-hydroxycholesterol is obtained from a patient sample, such as blood, plasma, serum, cerebrospinal fluid, circulatory and interstitial fluid levels, or a surgical specimen.
[0014] In certain embodiments, a value for the level of 24(S)-hydroxycholesterol is measured, hi certain embodiments, the value is compared to a control, e.g., the level of 24(S)-hydroxycholesterol in a patient sample.
[0015] In one embodiment, a method for assaying the level of 24(S)-hydroxycholesterol in a subject sample, comprising an agent capable of interacting with 24(S)-hydroxycholesterol (e.g., a probe, NMDA, or NMDAR); wherein the method comprises assaying the level of 24(S)-hydroxycholesterol.
[0016] In certain embodiments, 24(S)-hydroxycholesterol is obtained from a patient sample, such as blood, plasma, serum, cerebrospinal fluid, circulatory and interstitial fluid levels, or a surgical specimen.
[0017] In certain embodiments, a value for the level of 24(S)-hydroxycholesterol is measured, hi certain embodiments, the value is compared to a control, e.g., the level of 24(S)-hydroxycholesterol in a patient sample.
[0018] Also described herein, in one embodiment, is a reaction mixture that includes 24(S)-hydroxycholesterol and an agent that can interact with 24(S)-hydroxycholesterol (eg, a probe, NMDA, or NMDAR).
[0019] In one embodiment, a method of making a reaction mixture is also described herein, the method comprising: The method includes combining 24(S)-hydroxycholesterol with an agent capable of interacting with 24(S)-hydroxycholesterol (e.g., a probe, NMDA, or NMDAR).
[0020] The novel compounds described herein are potential NMDA receptor modulators (e.g., positive allosteric modulators (i.e., PAMs) or negative allosteric modulators (i.e., NAMs)) and may increase or decrease the intrinsic activity of 24(S)-hydroxycholesterol, thereby providing therapeutic benefits for a wide range of CNS-related conditions, including schizophrenia, depression, bipolar disorder (e.g., I and / or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), and the like. ), autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive-compulsive disorder (OCD), pain (e.g., painful syndrome or disorder), sleep disorder, memory disorder (e.g., memory dysfunction), dementia, Alzheimer's disease, seizure disorder (e.g., epilepsy), traumatic brain injury, stroke, addictive disorder (e.g., addiction to opiates, cocaine, and / or alcohol), autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndrome, or tinnitus. These compounds are expected to exhibit improved in vivo efficacy, pharmacokinetic (PK) properties, oral bioavailability, formulatability, stability, and / or safety. In some embodiments, the compounds described herein can be used to improve learning. In some embodiments, the compounds described herein can be used to treat an overdose, for example, a drug overdose (eg, a ketamine or PCP overdose).
[0021] The methods described herein, such as the evaluation and treatment methods, can be used with the compounds described herein. Exemplary compounds described herein include NMDAR agonists or NMDAR positive allosteric modulators (PAMs). In some embodiments, the compounds described herein are NMDAR negative allosteric modulators (NAMs). The compounds described herein also include naturally occurring and non-naturally occurring steroids and sterols (e.g., 24(S)-hydroxycholesterol). In some embodiments, the compounds are oxysterols. In some embodiments, the compounds are 3-β hydroxyl steroids with a C-17β side alkyl side chain and optional substitutions at various positions on the steroid skeleton, as shown in the compound of formula (I). In some embodiments, the methods are used in conjunction with a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., a compound that inhibits 24-hydroxycholesterol 7alpha-hydroxylase (CYP39)) or decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol, e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)).
[0022] In some embodiments, the compound used in the methods described herein, e.g., the methods of evaluation or treatment described herein, is a compound according to formula (I): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 , L 2 , L 3 , X 1 , X 2 , Y, R Z4 , R Z5 , R Z6 ,n,R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 6a , R 6b , R 7a , R 7b , R 11a , R 11b , R 14 , R 17 , R 19 , R 20 , R 23a , R 23b and R 24 is as defined herein; the group -XR at the C3 position 3b is either alpha or beta.
[0023] For example, in certain embodiments, the compound of formula (I) may be a compound of formula (Iw): [ka] or a pharmaceutically acceptable salt thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 and L 2 is selected from the group consisting of a bond, substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted heteroC1-C6 alkylene, substituted or unsubstituted heteroC2-C6 alkenylene, and substituted or unsubstituted heteroC2-C6 alkynylene; L 3 is a substituted or unsubstituted C1-C6 alkylene, a substituted or unsubstituted C2-C6 alkenylene, a substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero C1-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene; X 1 and X 2 each instance of is independently -O-, -S-, or -NH-; R 1 is hydrogen or substituted or unsubstituted alkyl; R 3b is hydrogen; R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R 2 , R 11a and R 11b Each instance of is independently hydrogen or -OR B1 where R B1 is hydrogen or substituted or unsubstituted alkyl, or R 11a and R 11b together form an oxo (=O) group; R 6a and R 6b each is independently hydrogen, halo, or substituted or unsubstituted alkyl; [ka] represents a single bond or a double bond, provided that if a double bond is present, R 6a or R 6b is absent and a single bond is present, the hydrogen at C5 is in the alpha or beta position; R 19 and R 20 Each instance of is independently hydrogen or -CH3; R 23a and R 23b Each instance of is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form a substituted or unsubstituted C3-C6 cycloalkyl; R 24 is hydrogen or substituted or unsubstituted alkyl; Y is -O-, -S- or -NR Z5 - and; R Z4 are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR Z5 , -SR Z5 or -N(R Z5 )2; R Z5 Each instance of is independently hydrogen or substituted or unsubstituted alkyl; R Z6 Each instance of is independently hydrogen or substituted or unsubstituted alkyl, or two R Z6 The group is connected to C 3-6 forming a carbocyclic ring; The subscript n is either 0 or 1; However, the following compounds are specifically excluded: [ka] In some embodiments, the compounds used in the methods described herein are [ka] is.
[0024] In certain embodiments, Z is a group of the formula: [ka]
[0025] In certain embodiments, L 3 is a radical of the formula: [ka] where p is 1, 2, or 3; R Z7 and R Z8 Each instance of is independently hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 is.
[0026] In certain embodiments, L 3 is a radical of the formula: [ka] wherein w is 0 or 1 and p is 1, 2, or 3, or w is 1 and p is 0, 1, 2, or 3; R Z7 and R Z8 Each instance of is independently hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 is.
[0027] In certain embodiments, L 3 is a radical of the formula: [ka]
[0028] In certain embodiments, L 3 is a radical of the formula: [ka]
[0029] In certain embodiments, L 3 is a radical of the formula: [ka]
[0030] In certain embodiments, Z is of the formula [ka] is.
[0031] In certain embodiments, the group [ka] is the following formula: [ka] [ka]
[0032] In certain embodiments, Z is of the formula [ka] is.
[0033] In certain embodiments, Y is —O— and L 3 is an alkylene group or a heteroalkylene group.
[0034] In certain embodiments, the group [ka] is the following formula: [ka]
[0035] In certain embodiments, Z is of the formula [ka] is.
[0036] In certain embodiments, Y is —O— and L 3 is alkylene or heteroalkylene.
[0037] In certain embodiments, the group [ka] is the following formula: [ka]
[0038] In certain embodiments, the group -X 1 R 3b is in the beta position, and R 3a is in the alpha position. In certain embodiments, -X 1 R 3b is —OH. In certain embodiments, R 3a is hydrogen. In certain embodiments, R 3ais substituted or unsubstituted alkyl. In certain embodiments, R 6b is halogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11b is hydrogen or -OR B1 and R 11a is hydrogen. In certain embodiments, R 11a and R 11b together form an oxo group. In certain embodiments, [ka] represents a single bond, and the hydrogen at C5 is in the alpha position. [ka] represents a double bond. In certain embodiments, R 19 is -CH3.
[0039] In another aspect, a pharmaceutical composition is provided that comprises a compound of the present invention and a pharmaceutically acceptable carrier.In certain embodiments, the compound of the present invention is provided in an effective amount.In certain embodiments, the compound of the present invention is provided in a therapeutically effective amount.In certain embodiments, the compound of the present invention is provided in a prophylactically effective amount.
[0040] In certain embodiments, the compounds of the present invention are provided as negative allosteric modulators (NAMs) of the NMDA receptor and are therefore useful for the prevention and / or treatment of a wide range of CNS conditions, including, but not limited to, schizophrenia, depression, bipolar disorder (I and II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive-compulsive disorder (OCD), all pain syndromes and disorders, sleep disorders, memory disorders and dementia (including Alzheimer's disease, epilepsy and any seizure disorder), traumatic brain injury (TBI), stroke, addictive disorders (including opiates and cocaine and alcohol), autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndromes or tinnitus. For example, in one embodiment, a method of modulating NMDA receptors is provided, comprising administering to a subject in need thereof an effective amount of a compound of the invention. In another embodiment, a method of modulating CNS activity is provided, comprising administering to a subject in need thereof an effective amount of a compound of the invention. In yet another embodiment, a method of modulating brain excitability is provided, comprising administering to a subject in need thereof an effective amount of a compound of the invention.
[0041] Other objects and advantages will become apparent to those skilled in the art from a consideration of the following detailed description, examples, and claims. In certain embodiments, for example, the following are provided: (Item 1) A method of evaluating or treating a patient, e.g., a patient having a disorder described herein, the method comprising: a) obtaining patient samples as needed; b) obtaining an assessment of and / or evaluating the sample for a change in the level of 24(S)-hydroxycholesterol as compared to a control standard; A method comprising: (Item 2) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of 24(S)-hydroxycholesterol or a structurally related sterol or steroid, an oxysterol, an agonist of NMDAR or a positive allosteric modulator (PAM) of NMDAR, or a compound described herein, such as a compound of Formula (I). (Item 3) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluation of said sample) an effective amount of an NMDAR antagonist or an NMDAR negative allosteric modulator (NAM). (Item 4) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol (e.g., a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39))). (Item 5) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of a compound that decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol (e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46))). (Item 6) 10. The method of claim 1, wherein the method further comprises treating the patient, wherein the patient is treated for memory impairment or is treated to improve learning. (Item 7) 10. The method of claim 1, further comprising treating the patient for drug overdose. DETAILED DESCRIPTION OF THE INVENTION
[0042] definition chemical definition Specific functional groups and chemical term definitions are explained in more detail below. Chemical elements are Elementary periodic table, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Further, general principles of organic chemistry, as well as specific functional moieties and reactivities, are described in detail in Thomas Sorrell, Organic Chemistry, Vol. Chemistry,University Science Books,Sausalito,1999;Smith and March,March's Advanced Organic Chemistry,5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987.
[0043] The compounds described herein may contain one or more asymmetric centers, and therefore may exist in various isomeric forms, such as enantiomers and / or diastereomers.For example, the compounds described herein may be in the form of individual enantiomers, diastereomers or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers.Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present invention further encompasses the compounds described herein as individual isomers substantially free of other isomers or as mixtures of various isomers.
[0044] When a range of values is recited, it is intended to encompass each value and subrange within that range. For example, "C 1-6 "Alkyl" refers to C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6, C 4-5 and C 5-6 Alkyl is intended to be included.
[0045] The following terms are intended to have the meanings presented therewith below and are useful in describing and understanding the intended scope of the present invention. In describing the present invention, which may include compounds, pharmaceutical compositions containing such compounds, and methods of using such compounds and compositions, the following terms, when present, have the following meanings unless otherwise indicated. As described herein, it should also be understood that any of the moieties defined below can be substituted with various substituents, and that each definition is intended to include such substituted moieties within their scope as set forth below. Unless otherwise stated, the term "substituted" should be defined as set forth below. It should further be understood that the terms "group" and "radical" can be considered interchangeable when used herein. The articles "a" and "an" can be used herein to refer to one or more than one (i.e., at least one) of the grammatical object of the article. By way of example, "an analogue" means one analogue or more than one analogue.
[0046] "Alkyl" means the radical of a straight- or branched-chain saturated hydrocarbon group having 1 to 20 carbon atoms ("C 1-20 In some embodiments, an alkyl group has 1 to 12 carbon atoms ("C 1-12 In some embodiments, an alkyl group has 1 to 10 carbon atoms ("C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C 1-9 In some embodiments, an alkyl group has 1 to 8 carbon atoms ("C 1-8 In some embodiments, an alkyl group has 1 to 7 carbon atoms ("C 1-7In some embodiments, an alkyl group has 1 to 6 carbon atoms (also referred to herein as "lower alkyl" or "C 1-6 In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C 1-5 In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C 1-4 In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C 1-3 In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C 1-2 In some embodiments, the alkyl group has one carbon atom ("C alkyl"). In some embodiments, the alkyl group has two to six carbon atoms ("C 2-6 alkyl). C 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Further examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkyl") or substituted with one or more substituents; for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent ("substituted alkyl"). In certain embodiments, an alkyl group is an unsubstituted C 1-10 In certain embodiments, the alkyl group is a substituted C 1-10Common abbreviations for alkyl include Me(-CH), Et(-CHCH), iPr(-CH(CH)), nPr(-CHCHCH), n-Bu(-CHCHCHCHCH) or i-Bu(-CHCH(CH)).
[0047] As used herein, "alkylene," "alkenylene," and "alkynylene" refer to divalent radicals of alkyl, alkenyl, and alkynyl groups, respectively. When a range or number of carbons is provided for a particular "alkylene," "alkenylene," and "alkynylene" group, it is understood that the range or number refers to the range or number of carbons in a linear, divalent carbon chain. "Alkylene," "alkenylene," and "alkynylene" groups can be substituted or unsubstituted with one or more substituents as described herein.
[0048] "Alkylene" refers to an alkyl group from which two hydrogens have been removed to provide a divalent radical, which can be substituted or unsubstituted. Unsubstituted alkylene groups include, but are not limited to, methylene (-CH-), ethylene (-CHCH-), propylene (-CHCHCH-), butylene (-CHCHCHCHCH-), pentylene (-CHCHCHCHCHCH-), hexylene (-CHCHCHCHCHCHCH-), and the like. Exemplary substituted alkylene groups, e.g., alkylene groups substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH)-, (-C(CH)-), substituted ethylene (-CH(CH)CH-, -CHCH(CH)-, -C(CH)CH-, -CHC(CH)-), substituted propylene (-CH(CH)CHCH-, -CHCH(CH)CH-, -CHCHCH(CH)-, -C(CH)CHCHCH-, -CHC(CH)CH-, -CHCHC(CH)-), and the like.
[0049] "Alkenyl" refers to the radical of a straight or branched chain hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds), and no triple bonds ("C 2-20 In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C 2-10 In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C 2-6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, an alkenyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, an alkenyl group has two carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be internal (e.g., 2-butenyl) or terminal (e.g., 1-butenyl). C 2-4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. 2-6 Examples of alkenyl groups include the above-mentioned C 2-4Alkenyl groups include pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Further examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkenyl") or substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent ("substituted alkenyl"). In certain embodiments, an alkenyl group is an unsubstituted C 2-10 In certain embodiments, the alkenyl group is a substituted C 2-10 It is alkenyl.
[0050] "Alkenylene" refers to an alkenyl group from which two hydrogens have been removed to provide a divalent radical, which can be substituted or unsubstituted. Exemplary unsubstituted divalent alkenylene groups include, but are not limited to, ethenylene (-CH=CH-) and propenylene (e.g., -CH=CHCH-, -CH-CH=CH-). Exemplary substituted alkenylene groups, e.g., alkenylene groups substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propylene (e.g., -C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.
[0051] "Alkynyl" refers to the radical of a straight- or branched-chain hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds), and optionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds) ("C 2-20Alkynyl groups having one or more triple bonds and one or more double bonds are also referred to as "ene-yene" groups. In some embodiments, alkynyl groups have 2 to 10 carbon atoms ("C 2-10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C 2-6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, an alkynyl group has two carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (e.g., 2-butynyl) or terminal (e.g., 1-butynyl). C 2-4 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. 2-6 Examples of alkenyl groups include the above-mentioned C 2-4Alkynyl groups include pentynyl (C5), hexynyl (C6), and the like. Further examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkynyl") or substituted with one or more substituents; for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent ("substituted alkynyl"). In certain embodiments, an alkynyl group is an unsubstituted C 2-10 In certain embodiments, the alkynyl group is a substituted C 2-10 It is alkynyl.
[0052] "Alkynylene" refers to a straight-chain alkynyl group from which two hydrogens have been removed to provide a divalent radical, which can be substituted or unsubstituted. Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, and the like.
[0053] The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, that further includes one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) in the parent chain, where the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain and / or where the one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In certain embodiments, a heteroalkyl group refers to a saturated group having 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC"). 1-10 In some embodiments, a heteroalkyl group refers to a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC 1-9 In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC1-8 In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC 1-7 In some embodiments, a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms ("heteroC 1-6 In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms ("heteroC 1-5 In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms ("heteroC 1-4 In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom ("heteroC 1-3 In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom ("heteroC 1-2 In some embodiments, the heteroalkyl group is a saturated group having one carbon atom and one heteroatom ("heteroC alkyl"). In some embodiments, the heteroalkyl group is a saturated group having 2 to 6 carbon atoms and one or two heteroatoms ("heteroC 2-6 Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an "unsubstituted heteroalkyl") or substituted with one or more substituents (a "substituted heteroalkyl"). In certain embodiments, a heteroalkyl group is an unsubstituted heteroC 1-10 In certain embodiments, the heteroalkyl group is a substituted heteroC 1-10 It is alkyl.
[0054] The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, that further contains one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus), where the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain and / or where the one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In certain embodiments, a heteroalkenyl group refers to a group having 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroalkenyl"). 2-10 In some embodiments, heteroalkenyl groups have 2 to 9 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2-9 In some embodiments, heteroalkenyl groups have 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2-8 In some embodiments, heteroalkenyl groups have 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2-7 In some embodiments, heteroalkenyl groups have 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms ("heteroC 2-6 In some embodiments, heteroalkenyl groups have 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms ("heteroC 2-5 In some embodiments, heteroalkenyl groups have 2 to 4 carbon atoms, at least one double bond, and 1 or 2 heteroatoms ("heteroC 2-4 In some embodiments, heteroalkenyl groups have 2 to 3 carbon atoms, at least one double bond, and one heteroatom ("heteroC 2-3In some embodiments, heteroalkenyl groups have 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms ("heteroC 2-6 Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an "unsubstituted heteroalkenyl") or substituted with one or more substituents (a "substituted heteroalkenyl"). In certain embodiments, a heteroalkenyl group is an unsubstituted heteroC 2-10 In certain embodiments, the heteroalkenyl group is a substituted heteroC 2-10 It is alkenyl.
[0055] The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, further containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus), where the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain and / or where the one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In certain embodiments, a heteroalkynyl group refers to a group having 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroalkynyl"). 2-10 In some embodiments, heteroalkynyl groups have 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC"). 2-9 In some embodiments, heteroalkynyl groups have 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2-8 In some embodiments, heteroalkynyl groups have 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2-7In some embodiments, heteroalkynyl groups have 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms ("heteroC 2-6 In some embodiments, heteroalkynyl groups have 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC 2-5 In some embodiments, heteroalkynyl groups have 2 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC 2-4 In some embodiments, heteroalkynyl groups have 2 to 3 carbon atoms, at least one triple bond, and one heteroatom ("heteroC 2-3 In some embodiments, heteroalkynyl groups have 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC 2-6 Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an "unsubstituted heteroalkynyl") or substituted with one or more substituents (a "substituted heteroalkynyl"). In certain embodiments, a heteroalkynyl group is an unsubstituted heteroC 2-10 In certain embodiments, the heteroalkynyl group is a substituted heteroC 2-10 It is alkynyl.
[0056] As used herein, "alkylene," "alkenylene," "alkynylene," "heteroalkylene," "heteroalkenylene," and "heteroalkynylene" refer to divalent radicals of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl groups, respectively. When a range or number of carbons is provided for a particular "alkylene," "alkenylene," "alkynylene," "heteroalkylene," "heteroalkenylene," or "heteroalkynylene" group, it is understood that the range or number refers to the range or number of carbons in a linear divalent carbon chain. "Alkylene," "alkenylene," "alkynylene," "heteroalkylene," "heteroalkenylene," and "heteroalkynylene" groups can be substituted or unsubstituted with one or more substituents as described herein.
[0057] "Aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a ring arrangement) having 6 to 14 ring carbon atoms and 0 heteroatoms provided as an aromatic ring system ("C 6-14 In some embodiments, an aryl group has 6 ring carbon atoms ("C aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 aryl"; e.g., naphthyl, e.g., 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C 14"Aryl"; e.g., anthracyl). "Aryl" also includes ring systems in which an aryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups, where the radical or point of attachment is on the aryl ring, and in such cases the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.In particular, aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted with one or more substituents ("substituted aryl"). In certain embodiments, an aryl group is an unsubstituted C 6-14 In certain embodiments, the aryl group is a substituted C 6-14 It is aryl.
[0058] In certain embodiments, the aryl group is substituted with one or more groups selected from halo, C1-C8 alkyl, C1-C8 haloalkyl, cyano, hydroxy, C1-C8 alkoxy, and amino.
[0059] Representative examples of substituted aryl include the following: [ka] In the formula, R 56 and R 57One of R can be hydrogen; 56 and R 57 At least one of the following is independently selected from C1-C8 alkyl, C1-C8 haloalkyl, 4- to 10-membered heterocyclyl, alkanoyl, C1-C8 alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 , N.R. 58 SOR 59 NR 58 SO2R 59 , COO alkyl, COO aryl, CONR 58 R 59 ,CONR 58 OR 59 , N.R. 58 R 59 , SO2NR 58 R 59 , S-alkyl, SO alkyl, SO alkyl, S aryl, SO aryl, SO aryl; or R 56 and R 57 may be connected to form a cyclic ring (saturated or unsaturated) of 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group of N, O, or S. R 60 and R 61 are independently hydrogen, C1-C8 alkyl, C1-C4 haloalkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 Aryl, substituted C6-C 10 It is aryl, 5- to 10-membered heteroaryl or substituted 5- to 10-membered heteroaryl.
[0060] Other representative aryl groups having a fused heterocyclyl group include: [ka] where each W is C(R 66 )2, NR 66 , O, and S; each Y is selected from carbonyl, NR 66, O and S; R 66 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.
[0061] "Fused aryl" refers to an aryl having two of its ring carbons in common with a second aryl or heteroaryl ring, or a carbocyclyl or heterocyclyl ring.
[0062] "Aralkyl" is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.
[0063] "Heteroaryl" refers to the radical of a 5- to 10-membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π-electrons shared in a ring arrangement) having ring carbon atoms and 1 to 4 ring heteroatoms provided as the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5- to 10-membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, if valence allows. Heteroaryl bicyclic ring systems can contain one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems in which a heteroaryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups, where the point of attachment is on the heteroaryl ring; in such cases, the number of ring members continues to refer to the number of ring members of the heteroaryl ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring, as defined above, is fused to one or more aryl groups, where the point of attachment can be on either the aryl ring or the heteroaryl ring, and in such cases the number of ring members refers to the number of ring members in the fused (aryl / heteroaryl) ring system. For bicyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., the ring with a heteroatom (e.g., 2-indolyl) or the ring without a heteroatom (e.g., 5-indolyl).
[0064] In some embodiments, heteroaryl groups are 5-10 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided as the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-8 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided as the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-6 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided as the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, 5-6 membered heteroaryls have 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5- to 6-membered heteroaryl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5- to 6-membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted with one or more substituents ("substituted heteroaryl"). In certain embodiments, a heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl. In certain embodiments, a heteroaryl group is a substituted 5- to 14-membered heteroaryl.
[0065] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0066] Representative examples of heteroaryls include: [ka] wherein each Y is a carbonyl, N, NR 65 , O and S; R 65 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.
[0067] "Heteroaralkyl" is a subset of alkyl and heteroaryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
[0068] "Carbocyclyl" or "carbocyclic" means a ring system having 3 to 10 ring carbon atoms ("C 3-10 In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C 5-10 carbocyclyl). Exemplary C 3-6 Carbocyclyl groups include, but are not limited to, cyclopropyl (C), cyclopropenyl (C), cyclobutyl (C), cyclobutenyl (C), cyclopentyl (C), cyclopentenyl (C), cyclohexyl (C), cyclohexenyl (C), cyclohexadienyl (C), and the like. 3-8 The carbocyclyl group includes the above-mentioned C 3-6Examples include, but are not limited to, carbocyclyl groups, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. 3-10 The carbocyclyl group includes the above-mentioned C 3-8 Carbocyclyl groups, as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 As the foregoing examples illustrate, in certain embodiments, a carbocyclyl group is monocyclic ("monocyclic carbocyclyl") or includes a fused, bridged, or spiro ring system (e.g., a bicyclic system) ("bicyclic carbocyclyl"), and can be saturated or partially unsaturated. "Carbocyclyl" also includes ring systems in which a carbocyclyl ring, as defined above, is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the carbocyclyl ring; in such cases, the number of carbons continues to refer to the number of carbons in the carbocyclyl ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted carbocyclyl") or substituted with one or more substituents ("substituted carbocyclyl"). In certain embodiments, a carbocyclyl group is an unsubstituted C 3-10 In certain embodiments, the carbocyclyl group is a substituted C 3-10 It is a carbocyclyl.
[0069] In some embodiments, "carbocyclyl" refers to a monocyclic saturated carbocyclyl group having 3 to 10 ring carbon atoms ("C 3-10In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C 5-6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C 5-10 Cycloalkyl). C 5-6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). 3-6 Examples of cycloalkyl groups include the above-mentioned C 5-6 Cycloalkyl groups include cyclopropyl (C3) and cyclobutyl (C4). 3-8 Examples of cycloalkyl groups include the above-mentioned C 3-6 Cycloalkyl groups include cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted ("unsubstituted cycloalkyl") or substituted with one or more substituents ("substituted cycloalkyl"). In certain embodiments, a cycloalkyl group is an unsubstituted C 3-10 In certain embodiments, the cycloalkyl group is a substituted C 3-10 It is cycloalkyl.
[0070] "Heterocyclyl" or "heterocyclic" refers to the radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("3- to 10-membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, when valence allows. Heterocyclyl groups can be monocyclic ("monocyclic heterocyclyl") or can be fused, bridged, or spiro ring systems, e.g., bicyclic systems ("bicyclic heterocyclyl"), saturated, or partially unsaturated. Heterocyclyl bicyclic ring systems can contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocyclyl ring, as defined above, is fused to one or more carbocyclyl groups (where the point of attachment is on the carbocyclyl ring or the heterocyclyl ring) or one or more aryl or heteroaryl groups (where the point of attachment is on the heterocyclyl ring); in such cases, the number of ring members continues to refer to the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted with one or more substituents ("substituted heterocyclyl"). In certain embodiments, a heterocyclyl group is an unsubstituted 3- to 10-membered heterocyclyl. In certain embodiments, a heterocyclyl group is a substituted 3- to 10-membered heterocyclyl.
[0071] In some embodiments, a heterocyclyl group is a 5- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("5- to 10-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5- to 8-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5- to 6-membered heterocyclyl"). In some embodiments, a 5- to 6-membered heterocyclyl has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0072] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azirdinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups (also referred to herein as 5,6-bicyclic heterocyclic rings) fused to a C6 aryl ring include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.Exemplary 6-membered heterocyclyl groups (also referred to herein as 6,6-bicyclic heterocyclic rings) fused to an aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0073] Particular examples of heterocyclyl groups are the following illustrative examples: [ka] where each W is the CR 67 , C(R 67 )2, NR 67 , O, and S; each Y is selected from NR 67 , O and S; R 67 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 and aryl and 5- to 10-membered heteroaryl. These heterocyclyl rings can be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (carbamoyl or amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, -S-alkyl, -S-aryl, -S(O)-alkyl, -S(O)-aryl, -S(O)2-alkyl, and -S(O)2-aryl. Substituents include, for example, carbonyl or thiocarbonyl, which provide lactam and urea derivatives.
[0074] "Hetero," when used to describe a compound or a group present on a compound, means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero can apply to any of the hydrocarbyl groups described above, such as alkyl, having 1 to 5, especially 1 to 3, heteroatoms (e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g., heteroaryl, cycloalkenyl, e.g., cycloheteroalkenyl, etc.).
[0075] "Acyl" means the radical -C(O)R 20 where R 20 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, as defined herein. "Alkanoyl" refers to a group in which R 20 is an acyl group where the aryl group is a group other than hydrogen. Representative acyl groups include formyl (-CHO), acetyl (-C(=O)CH3), cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl (-C(=O)Ph), benzylcarbonyl (-C(=O)CH2Ph), -C(O)-C1-C8 alkyl, and -C(O)-(CH2). t (C6-C 10 aryl), -C(O)-(CH2) t (5-10 membered heteroaryl), -C(O)-(CH2) t (C3-C 10 cycloalkyl) and -C(O)-(CH2) t (4-10 membered heterocyclyl) (wherein t is an integer from 0 to 4). In certain embodiments, R 21 is C1-C8 alkyl substituted with halo or hydroxy; or C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10Aryl, arylalkyl, 5-10 membered heteroaryl, or heteroarylalkyl, each of which is substituted with unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy or hydroxy.
[0076] "Acylamino" refers to the radical -NR 22 C(O)R 23 where R 22 and each instance of R23 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, as defined herein, or R 22 is an amino-protecting group. Exemplary "acylamino" groups include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino, and benzylcarbonylamino. Certain exemplary "acylamino" groups are -NR 24 C(O)-C1-C8 alkyl, -NR 24 C(O)-(CH2) t (C6-C 10 aryl), -NR 24 C(O)-(CH2) t (5-10 membered heteroaryl), -NR 24 C(O)-(CH2) t (C3-C 10 cycloalkyl) and -NR 24 C(O)-(CH2) t (4- to 10-membered heterocyclyl) (where t is an integer from 0 to 4), and each R 24 independently represent H or C1-C8 alkyl. In certain embodiments, R 25 is C1-C8 alkyl substituted with H, halo or hydroxy; C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C10 aryl, arylalkyl, 5-10 membered heteroaryl, or heteroarylalkyl, each of which is substituted with unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy or hydroxy; R 26 is C1-C8 alkyl substituted with H, halo or hydroxy; C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl, arylalkyl, 5-10 membered heteroaryl, or heteroarylalkyl, each of which is substituted with unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy, or hydroxyl; with the proviso that R 25 and R 26 At least one of is other than H.
[0077] "Acyloxy" is the radical -OC(O)R 27 where R 27 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, as defined herein. Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, and benzylcarbonyl. In certain embodiments, R 28 is C1-C8 alkyl substituted with halo or hydroxy; C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10Aryl, arylalkyl, 5-10 membered heteroaryl, or heteroarylalkyl, each of which is substituted with unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy or hydroxy.
[0078] "Alkoxy" refers to the group -OR 29 where R 29 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e., alkoxy having 1 to 6 carbon atoms. Further particular alkoxy groups have 1 to 4 carbon atoms.
[0079] In certain embodiments, R 29 is amino, substituted amino, C6-C 10 Aryl, aryloxy, carboxyl, cyano, C3-C 10 The "substituted alkoxy" group is a group having one or more substituents, for example, 1 to 5 substituents, particularly 1 to 3 substituents, and particularly 1 substituent, selected from the group consisting of cycloalkyl, 4- to 10-membered heterocyclyl, halogen, 5- to 10-membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)2-, and aryl-S(O)2-. Exemplary "substituted alkoxy" groups include -O-(CH2) t (C6-C 10 aryl), -O-(CH2) t (5-10 membered heteroaryl), -O-(CH2) t (C3-C 10cycloalkyl) and -O-(CH2) t (4-10 membered heterocyclyl) (where t is an integer from 0 to 4), any aryl, heteroaryl, cycloalkyl, or heterocyclyl group present may itself be substituted by unsubstituted C-C alkyl, halo, unsubstituted C-C alkoxy, unsubstituted C-C haloalkyl, unsubstituted C-C hydroxyalkyl, or unsubstituted C-C haloalkoxy or hydroxy. Certain exemplary "substituted alkoxy" groups are -OCF, -OCHCF, -OCHPh, -OCH-cyclopropyl, -OCHCHOH, and -OCHCHNMe.
[0080] "Amino" refers to the radical -NH2.
[0081] "Substituted amino" refers to a group of the formula -N(R 38 )2, where R 38 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an amino protecting group, wherein R 38 At least one of R is not hydrogen. 38 are independently hydrogen, C1-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, C6-C 10 Aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl or C3-C 10 cycloalkyl; or C1-C8 alkyl substituted with halo or hydroxy; C3-C8 alkenyl substituted with halo or hydroxy; C3-C8 alkynyl substituted with halo or hydroxy, or -(CH2) t (C6-C 10 aryl), -(CH2) t (5-10 membered heteroaryl), -(CH2) t (C3-C 10cycloalkyl) or -(CH2) t (4-10 membered heterocyclyl) (wherein t is an integer from 0 to 8), each of which is substituted by unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy; or both R 38 The groups are joined to form an alkylene group.
[0082] Exemplary "substituted amino" groups include -NR 39 -C1-C8 alkyl, -NR 39 -(CH2) t (C6-C 10 aryl), -NR 39 -(CH2) t (5-10 membered heteroaryl), -NR 39 -(CH2) t (C3-C 10 cycloalkyl) and -NR 39 -(CH2) t (4-10 membered heterocyclyl) (where t is an integer of 0 to 4, e.g., 1 or 2), and each R 39 independently represent H or C1-C8 alkyl; any alkyl groups present may themselves be substituted by halo, substituted or unsubstituted amino, or hydroxy; any aryl, heteroaryl, cycloalkyl, or heterocyclyl groups present may themselves be substituted by unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy or hydroxy. For the avoidance of doubt, the term "substituted amino" includes alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino, and substituted dialkylamino groups, as defined below. Substituted amino encompasses both mono- and di-substituted amino groups.
[0083] "Azide" refers to the radical -N3.
[0084] "Carbamoyl" or "amido" refers to the radical -C(O)NH2.
[0085] "Substituted carbamoyl" or "substituted amido" refers to a group consisting of the radical -C(O)N(R 62 )2, where each R 62 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an amino protecting group, wherein R 62 At least one of R is not hydrogen. 62 is H, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 Aryl, aralkyl, 5- to 10-membered heteroaryl and heteroaralkyl; or C1-C8 alkyl substituted with halo or hydroxy; or C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 selected from aryl, aralkyl, 5-10 membered heteroaryl or heteroaralkyl, each of which is substituted by unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy; provided that at least one R 62 is other than H.
[0086] Exemplary "substituted carbamoyl" groups include -C(O)NR 64 -C1-C8 alkyl, -C(O)NR 64 -(CH2) t (C6-C 10 aryl), -C(O)N 64 -(CH2) t (5-10 membered heteroaryl), -C(O)NR64 -(CH2) t (C3-C 10 cycloalkyl) and -C(O)NR 64 -(CH2) t (4- to 10-membered heterocyclyl) (where t is an integer of 0 to 4), and each R 64 independently represent H or C1-C8 alkyl, and any aryl, heteroaryl, cycloalkyl, or heterocyclyl group present may itself be substituted by unsubstituted C1-C4 alkyl, halo, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl, or unsubstituted C1-C4 haloalkoxy, or hydroxy.
[0087] "Carboxy" refers to the radical --C(O)OH.
[0088] "Cyano" refers to the radical -CN.
[0089] "Halo" or "halogen" refers to fluoro (F), chloro (Cl), bromo (Br), and iodo (I). In certain embodiments, a halo group is fluoro or chloro.
[0090] "Hydroxy" refers to the radical --OH.
[0091] "Nitro" refers to the radical -NO2.
[0092] "Cycloalkylalkyl" refers to an alkyl radical in which the alkyl group is substituted with a cycloalkyl group. Typical cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl.
[0093] "Heterocyclylalkyl" refers to an alkyl radical in which the alkyl group is substituted with a heterocyclyl group. Typical heterocyclylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.
[0094] "Cycloalkenyl" refers to substituted or unsubstituted carbocyclyl groups having from 3 to 10 carbon atoms, a single cyclic ring or multiple condensed rings (including fused and bridged ring systems), and at least 1, and especially 1 to 2, sites of olefinic unsaturation. Such cycloalkenyl groups include, by way of example, single-ring structures such as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.
[0095] "Fused cycloalkenyl" refers to a cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having olefinic unsaturation arranged in such a way as to confer aromaticity to the cycloalkenyl ring.
[0096] "Ethenyl" refers to a substituted or unsubstituted --(C.dbd.C)--.
[0097] "Ethylene" refers to a substituted or unsubstituted --(CC)--.
[0098] "Ethynyl" refers to -(C≡C)-.
[0099] A "nitrogen-containing heterocyclyl" group refers to a 4- to 7-membered non-aromatic cyclic group containing at least one nitrogen atom, such as, but not limited to, morpholine, piperidine (e.g., 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidine (e.g., 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkylpiperazines (e.g., N-methylpiperazine). Specific examples include azetidine, piperidone, and piperazone.
[0100] "Thioketo" refers to the group =S.
[0101] As defined herein, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl groups). In general, the term "substituted," whether preceded by the term "optionally" or not, means that at least one hydrogen atom present in a group (e.g., a carbon atom or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent that, upon substitution, results in a stable compound, e.g., a compound that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, or other reaction, etc. Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituents may be the same or different at each position. The term "substituted" is intended to include substitution of any of the substituents described herein with all permissible substituents of organic compounds, which results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituents, as described herein, which satisfy the valence of the heteroatom and result in the formation of a stable moiety.
[0102] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa , -ON(R bb )2, -N(R bb )2, -N(R bb )3 + X - , -N(OR cc )R bb , -SH, -SR aa , -SSR cc , -C(=O)Raa 、-CO2H、-CHO、-C(OR cc )2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2Raa , -P(=O)(R aa )2, -OP(=O)(R aa )2, -OP(=O)(OR cc )2, -P(=O)2N(R bb )2, -OP(=O)2N(R bb )2, -P(=O)(NR bb )2, -OP(=O)(NR bb )2, -NR bb P(=O)(OR cc )2, -NR bb P(=O)(NR bb )2, -P(R cc )2, -P(R cc )3, -OP(R cc )2, -OP(R cc )3, -B(R aa )2, -B(OR cc )2, -BR aa (OR cc ), C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 and 5- to 14-membered heteroaryl, wherein each of alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd Is substituted with a group; or two geminal hydrogens on a carbon atom can be bonded to the groups =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb or =NOR cc Replaced by; R aa Each instance of 1-10 Alkyl, C 1-10 Perhaloalkyl, C2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two R aa The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each of the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R bb Each instance of is independently hydrogen, -OH, -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)2N(R cc )2, -P(=O)(NR cc )2,C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two R bbThe groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each of the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R cc Each instance of 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl, or two R cc The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each of the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R dd Each instance of is independently a halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee , -ON(R ff )2, -N(R ff )2, -N(R ff )3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -CO2H, -CO2R ee , -OC(=O)R ee , -OCO2R ee , -C(=O)N(R ff )2, -OC(=O)N(R ff )2, -NR ff C(=O)R ee , -NR ff CO2R ee , -NR ff C(=O)N(R ff)2, -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2, -NR ff C(=NR ff )N(R ff )2,-NR ff SO2R ee , -SO2N(R ff )2, -SO2R ee , -SO2OR ee , -OSO2R ee , -S(=O)R ee , -Si(R ee )3, -OSi(R ee )3, -C(=S)N(R ff )2, -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)2R ee , -P(=O)(R ee )2, -OP(=O)(R ee )2, -OP(=O)(OR ee )2, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, wherein each of alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group or two geminal R dd The substituents may together form =O or =S; R ee Each instance of 1-6 Alkyl, C 1-6 Perhaloalkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl, wherein each of alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R ff Each instance of 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5- to 10-membered heteroaryl, or two R ff The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each of the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R gg Each instance of is independently a halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 alkyl)2, -N(C 1-6 alkyl)2, -N(C 1-6 Alkyl)3 + X - , -NH(C 1-6 alkyl)2 + X - , -NH2(C 1-6 alkyl) + X - , -NH3 + X - , -N(OC 1-6 Alkyl)(C 1-6 alkyl), -N(OH)(C 1-6 alkyl), -NH(OH), -SH, -SC 1-6Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3-C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two geminal R gg The substituents may together form =O or =S; where X - is the counter ion.
[0103] A "counterion" or "anionic counterion" is a negatively charged group associated with a cationic quaternary amino group to maintain electrical neutrality. Exemplary counterions include halide ions (e.g., F - , Cl - , Br - , I-), NO3 - , ClO4 - , O.H. - , H2PO4 - , HSO4 - , sulfonate ions (e.g., methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphorsulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid, etc.) and carboxylate ions (e.g., acetic acid, ethanoic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartaric acid, glycolic acid, etc.).
[0104] Nitrogen atoms can be substituted or unsubstituted, where valence allows, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substitutents include hydrogen, -OH, -ORaa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)2N(R cc )2, -P(=O)(NR cc )2, C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, or two R attached to a nitrogen atom cc The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each of the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with R aa , R bb , R cc and R dd is as defined above.
[0105] In certain embodiments, the substituent present on the nitrogen atom is an amino protecting group (also referred to herein as a nitrogen protecting group). Amino protecting groups include -OH, -OR aa , -N(R cc )2, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , C 1-10 Alkyl (e.g., aralkyl, heteroaralkyl), C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6-14 and 5- to 14-membered heteroaryl groups, where each of alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with R aa , R bb , R cc and R dd is as defined herein. Amino protecting groups are well known in the art and include those described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M.Wuts, 3 rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference.
[0106] For example, an amino protecting group such as an amide group (e.g., —C(═O)R aa ) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.
[0107] an amino protecting group such as a carbamate group (e.g., —C(═O)OR aa), methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), ), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'- and and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropyl allyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyl dithiocarbamate, benzoyl Dicarbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenylcarbamate (Mtpc), 2,4-dimethylthiophenylcarbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropylcarbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonyl methyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzylthiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethicone Oxyacyl vinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobornyl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutylcarbamate methyl 1-(4-pyridyl)ethyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,Examples include, but are not limited to, 6-trimethylbenzylcarbamate.
[0108] Amino protecting groups such as sulfonamide groups (e.g., -S(=O)R aa ) include p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6 -dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
[0109] Other amino protecting groups include phenothiazinyl-(10)-acyl derivatives, N'-p-toluenesulfonylaminoacyl derivatives, N'-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, and N-1,1,4,4-tetramethyldisilylaza. Cyclopentane adducts (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-ones, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-ones, 1-substituted 3,5-dinitro-4-pyridones, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl) Amines, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethylthio Methyleneamine, N-benzylideneamine, Np-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, Np-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,These include, but are not limited to, 5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylborinic acid derivatives, N-[phenyl(pentaacylchromium or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidate, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridine sulfenamide (Npys).
[0110] In certain embodiments, the substituent present on the oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group). Oxygen protecting groups include -R aa , -N(R bb )2, -C(=O)SR aa , -C(=O)R aa , -CO2R aa , -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa ) 3、 -P(R cc )2, -P(R cc )3, -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)2N(R bb )2, and -P(=O)(NR bb )2, where Raa , R bb and R cc is as defined herein. Oxygen protecting groups are well known in the art and include those described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Buts, 3 rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference.
[0111] Exemplary oxygen protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), and the like. ), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4 -Methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethoxyethyl ethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-Dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate Acetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyl dithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-Trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate, alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzene Dimethylbenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-napthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzyl Benzene sulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)- These include, but are not limited to, 2-methyl-2-butenoate, o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).
[0112] In certain embodiments, the substituent present on the sulfur atom is a sulfur protecting group (also referred to as a thiol protecting group). Sulfur protecting groups include -R aa , -N(R bb )2, -C(=O)SR aa , -C(=O)R aa , -CO2Raa , -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa ) 3、 -P(R cc )2, -P(R cc )3, -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)2N(R bb )2, and -P(=O)(NR bb )2, where R aa , R bb and R cc is as defined herein. Sulfur protecting groups are well known in the art and include those described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Buts, 3 rd edition,John Wiley & Sons, 1999, incorporated herein by reference.
[0113] "Compounds of the invention" and equivalent expressions are meant to include compounds as described herein above, particularly compounds according to any of the formulae listed and / or described herein, and the expression includes prodrugs, pharmaceutically acceptable salts and solvates, e.g., hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to include their salts and solvates, where the context so permits.
[0114] These and other exemplary substituents are described in more detail in the detailed description, examples, and claims. It is not intended that the present invention be limited in any way by the above exemplary list of substituents.
[0115] Other definitions "Pharmaceutically acceptable" means approved or capable of being approved by a regulatory authority of the federal or state government or a corresponding authority in a country other than the United States, or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0116] "Pharmaceutically acceptable salts" refers to salts of compounds of the present invention that are pharmaceutically acceptable and that possess the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and can be inorganic or organic acid addition salts and inorganic or organic base addition salts. Specifically, such salts include: (1) acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.); or organic acids (e.g., acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphor acid, etc.). or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc.). Salts further include, by way of example only, salts of sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and, when the compound contains a basic functional group, salts of non-toxic organic or inorganic acids (e.g., hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, etc.). The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group.Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, eg, Berge, et al., J. Pharm. Sci. 66(1):1-79 (Jan. 1977)).
[0117] "Pharmaceutically acceptable vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered.
[0118] "Pharmaceutically acceptable metabolically cleavable group" refers to a group that is cleaved in vivo to yield a parent molecule of the structural formula shown herein. Examples of metabolically cleavable groups include -COR, -COOR, -CONRR and -CH2OR radicals, where R is independently selected at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl, or carbocyclic aryl substituted with one or more alkyl, halogen, hydroxy or alkoxy groups. Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.
[0119] The term "prodrug" refers to a compound (including derivatives of the compounds of the present invention) that has a cleavable group and becomes a pharmaceutically active compound of the present invention in vivo upon solvolysis or under physiological conditions. Examples include, but are not limited to, choline ester derivatives, N-alkylmorpholine esters, and the like. Other derivatives of the compounds of the present invention are active in both their acid and acid-derivative forms, but often the acid-sensitive form offers advantages of solubility, tissue compatibility, or delayed release in mammalian organisms (see Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to those skilled in the art, such as esters prepared by reacting the parent acid with a suitable alcohol, or amides prepared by reacting the parent acid compound with a substituted or unsubstituted amine, acid anhydride, or mixed anhydride. Simple aliphatic or aromatic esters, amides, and anhydrides derived from pendant acidic groups on the compounds of the present invention are particular prodrugs. In some cases, it may be desirable to prepare double ester type prodrugs (e.g., (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters). In particular, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C8 alkyl esters of the compounds of the invention may be prepared. 12 Substituted Aryl and C7-C 12 Aryl alkyl esters.
[0120] "Solvate" refers to a form of a compound that is associated with a solvent or with water, usually by solvolysis (also referred to as a "hydrate"). This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid, and the like. The compounds of the present invention can be prepared, for example, in crystalline form, and can be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates (e.g., hydrates), and further include both stoichiometric and non-stoichiometric solvates. In certain cases, a solvate may be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
[0121] "Subjects" to which administration is contemplated include, but are not limited to, humans (i.e., male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or an adult subject (e.g., young adult, middle-aged adult, or geriatric)) and / or non-human animals, e.g., mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs). In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.
[0122] An "effective amount" means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention. The "effective amount" may vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated. A "therapeutically effective amount" refers to an amount effective for therapeutic treatment. A "prophylactically effective amount" refers to an amount effective for prophylactic treatment.
[0123] "Preventing" or "prevention" or "prophylactic treatment" refers to reducing the risk of acquiring or developing a disease or disorder (i.e., preventing at least one clinical sign of the disease from developing in a subject who has not yet been exposed to a pathogen or who has a predisposition to the disease prior to the onset of the disease).
[0124] The term "prophylaxis" is related to "prevention" and refers to a measure or procedure whose purpose is to prevent, rather than treat or cure, a disease. Non-limiting examples of prophylactic measures can include the administration of a vaccine; the administration of low molecular weight heparin to hospitalized patients who are at risk of thrombosis, for example, due to restraint; and the administration of an antimalarial agent such as chloroquine prior to visiting a geographic area where malaria is endemic or where there is an increased risk of contracting malaria.
[0125] "Treating" any disease or disorder or "treatment" or "therapeutic treatment" of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., halting the disease or reducing the manifestation, extent, or severity of at least one of its clinical signs). In another embodiment, "treating" or "treatment" refers to ameliorating at least one physical parameter, which amelioration may not be discernible by the subject. In yet another embodiment, "treating" or "treatment" refers to either physically modulating the disease or disorder (e.g., stabilizing discernible symptoms), physiologically modulating the disease or disorder (e.g., stabilizing physiological parameters), or both. In a further embodiment, "treating" or "treatment" relates to slowing the progression of the disease.
[0126] As used herein, the term "isotopic variant" refers to a compound that contains unnatural proportions of isotopes at one or more atoms that constitute such compound. For example, an "isotopic variant" of a compound may contain one or more non-radioactive isotopes, such as deuterium ( 2 H or D), carbon-13 (13 C), nitrogen-15( 15 In compounds having such isotopic substitutions, the following atoms, if present, may be present: for example, any hydrogen 2 H / D or any carbon 13 C or any nitrogen 15 It will be understood that the presence and location of atoms can vary, such as N, and that the presence and location of such atoms can be determined within the skill of the art. Similarly, the present invention can include the preparation of isotopic variants with radioactive isotopes, where, for example, the resulting compounds can be used in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e., 3 H, and carbon-14, i.e. 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection. Additionally, positron-emitting isotopes (e.g., 11 C. 18 F, 15 O and 13 N) substituted compounds can be prepared that would be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. All isotopic variations of the compounds provided herein, radioactive or not, are intended to be encompassed within the scope of the present invention.
[0127] It should also be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."
[0128] Stereoisomers that are not mirror images of one another are called "diastereomers," and those that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, when it is bonded to four different groups, a pair of enantiomers can exist. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0129] "Tautomers" refer to interchangeable forms of a particular compound structure that differ in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and atoms (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenylnitromethane, which are also formed by treatment with acid or base. Tautomers can be valuable in achieving optimal chemical reactivity and biological activity of a desired compound.
[0130] As used herein, a pure enantiomer is substantially free of other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound and is thus in enantiomeric excess of the "R" form. The terms "enantiomerically pure" or "pure enantiomer" indicate that a compound contains more than 75%, more than 80%, more than 85%, more than 90%, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 98.5%, more than 99%, more than 99.2%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9% by weight of an enantiomer. In certain embodiments, the weight is based on the total weight of all enantiomers or stereoisomers of the compound.
[0131] As used herein, unless otherwise indicated, the term "enantiomerically pure R-compounds" refers to at least about 80% by weight of R-compounds and at most about 20% by weight of S-compounds, at least about 90% by weight of R-compounds and at most about 10% by weight of S-compounds, at least about 95% by weight of R-compounds and at most about 5% by weight of S-compounds, at least about 99% by weight of R-compounds and at most about 1% by weight of S-compounds, at least about 99.9% by weight of R-compounds, or at most about 0.1% by weight of S-compounds. In certain embodiments, the weights are based on the total weight of the compounds.
[0132] As used herein, unless otherwise indicated, the term "enantiomerically pure S-compound" or "S-compound" refers to at least about 80% by weight of S-compounds and at most about 20% by weight of R-compounds, at least about 90% by weight of S-compounds and at most about 10% by weight of R-compounds, at least about 95% by weight of S-compounds and at most about 5% by weight of R-compounds, at least about 99% by weight of S-compounds and at most about 1% by weight of R-compounds, or at least about 99.9% by weight of S-compounds and at most about 0.1% by weight of R-compounds. In certain embodiments, the weights are based on the total weight of the compounds.
[0133] In the compositions provided herein, the enantiomerically pure compound or its pharmaceutically acceptable salt, solvate, hydrate, or prodrug may be present together with other active or inactive ingredients. For example, a pharmaceutical composition containing an enantiomerically pure R-compound may contain, for example, about 90% excipient and about 10% enantiomerically pure R-compound. In certain embodiments, the enantiomerically pure R-compound in such a composition may contain, for example, at least about 95% by weight of the R-compound and at most about 5% by weight of the S-compound, based on the total weight of the compound. For example, a pharmaceutical composition containing an enantiomerically pure S-compound may contain, for example, about 90% excipient and about 10% of the enantiomerically pure S-compound. In certain embodiments, the enantiomerically pure S-compound in such a composition may contain, for example, at least about 95% by weight of the S-compound and at most about 5% by weight of the R-compound, based on the total weight of the compound. In certain embodiments, the active ingredients may be formulated with few or no excipients or carriers.
[0134] The compounds of the present invention may possess one or more asymmetric centers; therefore, such compounds can be produced as individual (R)- or (S)-stereoisomers or mixtures thereof.
[0135] Unless otherwise indicated, the description or reference to a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures thereof, racemic or not. Methods for determining stereochemistry and for separating stereoisomers are well-known in the art.
[0136] Those skilled in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, regardless of whether the ring is aromatic or non-aromatic, is determined by the size of the ring, the degree of unsaturation, and the valence of the heteroatoms. Generally, a heterocyclic ring can have from 1 to 4 heteroatoms, so long as the aromatic heterocycle is chemically feasible and stable. Detailed Description of Certain Embodiments of the Invention
[0137] In certain embodiments, provided herein are 3-alpha and 3beta-hydroxysteroid compounds useful as NMDA receptor modulators and therefore for the prevention and / or treatment of a wide range of CNS conditions, including, inter alia, schizophrenia, depression, bipolar disorder (e.g., I and / or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive-compulsive disorder (OCD), pain (e.g., painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's disease, seizure disorders (e.g., epilepsy), traumatic brain injury, stroke, addictive disorders (e.g., addiction to opiates, cocaine, and / or alcohol), autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. These compounds are expected to exhibit improved in vivo efficacy, pharmacokinetic (PK) properties, oral bioavailability, formulation suitability, stability and / or safety.
[0138] compound Exemplary compounds described herein include NMDAR agonists or NMDAR positive allosteric modulators (PAMs).In some embodiments, compounds described herein include NMDAR antagonists or NAMs.Compounds described herein include naturally occurring and non-naturally occurring steroids and sterols (e.g., 24(S)-hydroxycholesterol).In some embodiments, the compound is an oxysterol.In some embodiments, the compound is a 3-β hydroxyl steroid with a C-17β alkyl side chain and optional substitutions at various positions on the steroid skeleton, as shown in the compound of formula (I). Further exemplary compounds include compounds that enhance (e.g., increase) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., compounds that inhibit an enzyme that metabolizes 24(s)-hydroxycholesterol, e.g., compounds that inhibit 24-hydroxycholesterol 7alpha-hydroxylase (CYP39)) or compounds that decrease the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., compounds that activate an enzyme that produces 24(s)-hydroxycholesterol, e.g., compounds that activate cholesterol 24(S)-hydroxylase (CYP46)).
[0139] In some embodiments, the compound used in the methods described herein, e.g., the methods of evaluation or treatment described herein, is a compound according to formula (I): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 and L 2 is selected from the group consisting of a bond, substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted heteroC1-C6 alkylene, substituted or unsubstituted heteroC2-C6 alkenylene, and substituted or unsubstituted heteroC2-C6 alkynylene; L 3 is a substituted or unsubstituted C1-C6 alkylene, a substituted or unsubstituted C2-C6 alkenylene, a substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero C1-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene; X 1 and X 2 Each instance of may independently be -O-, -S-, -N(R X )-, where R X each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group; R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N3, -NO2, -SCN, -CN, -OR A1 , -SR A1 , -N(R A1 )2, -N=NR A1 , -N=C(R A1 )2, -N(OR A1 )(R A1 ), -C(=O)R A1 , -C(=O)OR A1 , -C(=O)SR A1 , -C(=O)N(RA1 )2, -C(=O)N(OR A1 )(R A1 ), -OC(=O)R A1 , -OC(=O)OR A1 , -OC(=O)SR A1 , -OC(=O)N(R A1 )2, -NR A1 C(=O)R A1 , -NR A1 C(=O)OR A1 , -NR A1 C(=O)SR A1 , -NR A1 C(=O)N(R A1 )2, -SC(=O)R A2 , -SC(=O)OR A1 , -SC(=O)SR A1 , -SC(=O)N(R A1 )2, -OS(=O)2R A2 , -OS(=O)2OR A1 , -SS(=O)2R A2 , -SS(=O)2OR A1 , -S(=O)R A2 , -SO2R A2 , -NR A1 SO2R A2 , or -SO2N(R A1 )2, where R A1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R A1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R A2 is a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R A1 Groups and RA2 the groups are joined to form a substituted or unsubstituted heterocyclic ring; R 2 , R 4a , R 4b , R 7a , R 7b , R 11a and R 11b Each instance of is independently selected from hydrogen, —OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —N, —NO, —SCN, —CN, —OR B1 , -SR B1 , -N(R B1 )2, -N=NR B1 , -N=C(R B1 )2, -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 )2, -C(=O)N(OR B1 )(R B1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 )2, -NR B1 C(=O)R B1 , -NR B1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 )2, -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 )2, -OS(=O)2R B2 , -OS(=O)2OR B1 , -SS(=O)2R B2 , -SS(=O)2OR B1, -S(=O)R B2 , -SO2R B2 , -NR B1 SO2R B2 , or -SO2N(R B1 )2, where R B1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R B2 is a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R B1 Groups and R B2 groups may be joined to form a substituted or unsubstituted heterocyclic ring; or optionally, R 4a and R 4b and / or R 7a and R 7b and / or R 11a and R 11b each taken together form an oxo (=O) group; R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3b is hydrogen, -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 )2, -S(=O)2R C2 , -S(=O)2ORC1 , -P(=O)2R C2 , -P(=O)2OR C1 , -P(=O)(OR C1 )2, -P(=O)(R C2 )2, or -P(=O)(R C2 )(OR C1 ), where R C1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R C1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R C2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; R 6a and R 6b each is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; [ka] represents a single bond or a double bond, provided that when a double bond is present in ring B, R 6a or R 6b is absent and a single bond is present in ring B, then the hydrogen at C5 is in the alpha or beta position; R 14 is hydrogen or substituted or unsubstituted alkyl; R 17is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -OR D1 where R D1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; R 18 , R 19 and R 20 Each instance of is independently hydrogen or substituted or unsubstituted alkyl; R 23a and R 23b Each instance of is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form a substituted or unsubstituted C3-C6 cycloalkyl; R 24 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)R E1 , -C(=O)OR E1 , -C(=O)SR E1 , -C(=O)N(R E1 )2, -S(=O)2R E2 , -S(=O)2OR E1 , -P(=O)2R E2 , -P(=O)2OR E1 , -P(=O)(OR E1 )2, -P(=O)(R E2 )2, or -P(=O)(R E2 )(OR E1 ), where R E1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R E1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R E2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; Y is -O-, -S- or -NR Z5 - and; R Z4 are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR Z5 , -SR Z5 or -N(R Z5 )2; R Z5 Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R Z5 the groups are joined to form a substituted or unsubstituted heterocyclic ring; R Z6 Each instance of is independently hydrogen or substituted or unsubstituted alkyl, or two R Z6 The group is connected to C 3-6 forming a carbocyclic ring; The subscript n is 0, 1, 2 or 3.
[0140] In certain embodiments, R 3a is H, n is 1, and R 19 When Me is ;R 1 is other than H, alkyl, alkenyl, or alkynyl. In certain embodiments, R 3a is H and R 3b is -COMe and R 19 When Me and n is 0; R 1 is OH. In certain embodiments, R 3a is H, n is 0, and R 20 is alkyl; R 1 is other than OH. In certain embodiments, R 19 When Me is ;R 1 is other than H, alkyl, alkenyl, or alkynyl. In certain embodiments, R 1 is H;R 19 is other than Me. In certain embodiments, R 1 and R 3a Each of is H; 19 is other than Me.
[0141] In certain embodiments, R 3a When H, R 1 is other than H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. 3a When H, R 1 is a substituted or unsubstituted carbocyclyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, halo, -N3, -NO2, -SCN, -CN, -OR A1 , -SR A1 , -N(R A1 )2, -N=NR A1 , -N=C(R A1 )2, -N(OR A1 )(RA1 ), -C(=O)R A1 , -C(=O)OR A1 , -C(=O)SR A1 , -C(=O)N(R A1 )2, -C(=O)N(OR A1 )(R A1 ), -OC(=O)R A1 , -OC(=O)OR A1 , -OC(=O)SR A1 , -OC(=O)N(R A1 )2, -NR A1 C(=O)R A1 , -NR A1 C(=O)OR A1 , -NR A1 C(=O)SR A1 , -NR A1 C(=O)N(R A1 )2, -SC(=O)R A2 , -SC(=O)OR A1 , -SC(=O)SR A1 , -SC(=O)N(R A1 )2, -OS(=O)2R A2 , -OS(=O)2OR A1 , -SS(=O)2R A2 , -SS(=O)2OR A1 , -S(=O)R A2 , -SO2R A2 , -NR A1 SO2R A2 , or -SO2N(R A1 )2.
[0142] In certain further embodiments, the following compound: [ka] and pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers, tautomers, isotopic variants or N-oxides thereof, or combinations thereof, are specifically excluded.
[0143] R 3a Various embodiments of As generally defined above, R 3a R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. 3a It is broadly understood that R can be in the alpha position (bottom) or the beta position (top). 3a is alpha. In certain embodiments, R 3a is beta.
[0144] In certain embodiments, R 3a is hydrogen.
[0145] In certain embodiments, R 3a is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. 3a C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Examples include, but are not limited to, alkyl (e.g., —CH2OCH3 and —CH2OCH2CH3). In certain embodiments, R 3a is a substituted alkyl, for example, R 3a is haloalkyl, alkoxyalkyl, or aminoalkyl. In certain embodiments, R 3a is Me, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoro-1,1-dimethyl-ethyl, methoxymethyl, methoxyethyl, or ethoxymethyl. 3a is Me, Et, n-Pr, n-Bu, or i-Bu. 3a is methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, or ethoxyethyl. In certain embodiments, R 3a is trifluoromethoxymethyl. In certain embodiments, R 3a is fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, or 2,2,2-trifluoro-1,1-dimethyl-ethyl. 3a is trifluoromethyl.
[0146] In certain embodiments, R 3a is a substituted or unsubstituted alkenyl, for example, a substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 In certain embodiments, R is alkenyl. 3ais ethenyl (C2), propenyl (C3), or butenyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R 3a is ethenyl, propenyl, or butenyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxy. In certain embodiments, R 3a is ethenyl.
[0147] In certain embodiments, R 3a is a substituted or unsubstituted alkynyl, for example, a substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 alkynyl. Exemplary substituted or unsubstituted R 3a Alkynyl groups include, but are not limited to, ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl (e.g., CF), alkoxyalkyl, cycloalkyl (e.g., cyclopropyl or cyclobutyl), or hydroxyl. In certain embodiments, R 3a is selected from the group consisting of trifluoroethynyl, cyclopropylethynyl, cyclobutylethynyl, and propynyl, fluoropropynyl, and chloroethynyl. 3a is ethynyl (C2), propynyl (C3), or butynyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl. In certain embodiments, R 3ais ethynyl (C2), propynyl (C3), or butynyl (C4) substituted with a substituted phenyl. In certain embodiments, the phenyl substitutent is further substituted with one or more substituents selected from the group consisting of halo, alkyl, trifluoroalkyl, alkoxy, acyl, amino, or amido. In certain embodiments, R 3a is ethynyl (C2), propynyl (C3) or butynyl (C4) substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl.
[0148] In certain embodiments, R 3a is ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R 3a is ethynyl or propynyl substituted with substituted or unsubstituted aryl. In certain embodiments, R 3a is ethynyl or propynyl substituted with unsubstituted phenyl or phenyl substituted with halo, alkyl, alkoxy, haloalkyl, trihaloalkyl, or acyl. 3a is ethynyl or propynyl substituted with a substituted or unsubstituted carbocyclyl. 3a is ethynyl or propynyl, substituted or unsubstituted with cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 3a is ethynyl or propynyl substituted with substituted or unsubstituted heteroaryl. 3a is substituted or unsubstituted, pyridinyl or pyrimidinyl, ethynyl or propynyl. In certain embodiments, R 3ais ethynyl or propynyl substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl. In certain embodiments, R 3a is ethynyl or propynyl substituted with substituted or unsubstituted heterocyclyl. 3a is ethynyl or propynyl substituted with substituted or unsubstituted pyrrolidinyl, piperidinyl, piperazinyl, or mopholinyl. In certain embodiments, R 3a is propynyl or butynyl substituted with hydroxyl or alkoxy. In certain embodiments, R 3a is propynyl or butynyl substituted with methoxy or ethoxy. 3a is ethynyl or propynyl substituted with Cl. In certain embodiments, R 3a is ethynyl or propynyl substituted with trifluoromethyl.
[0149] In certain embodiments, R 3a is a substituted or unsubstituted carbocyclyl, for example, a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 It is a carbocyclyl.
[0150] In certain embodiments, R 3a is a substituted or unsubstituted heterocyclyl, for example, a substituted or unsubstituted 3- to 6-membered heterocyclyl, a substituted or unsubstituted 3- to 4-membered heterocyclyl, a substituted or unsubstituted 4- to 5-membered heterocyclyl, or a substituted or unsubstituted 5- to 6-membered heterocyclyl.
[0151] In certain embodiments, R3a is substituted or unsubstituted aryl. In certain embodiments, R 3a is substituted or unsubstituted phenyl.
[0152] In certain embodiments, R 3a is a substituted or unsubstituted heteroaryl, for example, an optionally substituted 5- to 6-membered heteroaryl.
[0153] R 3a Further embodiments of the present invention include the following as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl groups: [ka] where R 3c Each instance of -OR is hydrogen, halo, or -OR F1 where R F1 is substituted or unsubstituted alkyl; R 3d Each instance of is hydrogen, halo, or substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl.
[0154] In certain embodiments, at least one R 3c is hydrogen. In certain embodiments, at least two R 3c is hydrogen. In certain embodiments, each R 3c is hydrogen. In certain embodiments, at least one R 3c is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, at least two R 3c is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3c is halogen (e.g., fluoro, providing the group -CF). In certain embodiments, at least one R 3c -OR F1(e.g., OMe or OEt). In certain embodiments, at least two R 3c -OR F1 (e.g., OMe or OEt). In certain embodiments, at least one R 3c is hydrogen, F, -OMe, or -OEt. 3c one of which is F, -OMe, or OEt; the other is H.
[0155] In certain embodiments, at least one R 3d is hydrogen. In certain embodiments, each R 2c is hydrogen. In certain embodiments, at least one R 3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3d is alkyl, e.g., each R 2c is Me. In certain embodiments, one R 3d is alkyl; and the other is hydrogen, e.g., one R 3d is Me; and the other is hydrogen. In certain embodiments, one R 3d is a substituted or unsubstituted carbocyclyl, e.g., cyclopropyl or cyclobutyl, and the other is hydrogen. In certain embodiments, at least one R 3d is hydrogen, -F, -Br, -Cl, -I, -CH, -CF, cyclopropyl, or cyclobutyl. 3d Each instance of R is H. In certain embodiments, R 3d Each instance of R is halogen (e.g., fluoro, chloro, bromo, iodo). 3d Each instance of R is alkyl, e.g., —CH, —CF, —CHCHCl. In certain embodiments, R 3dEach instance of R is a substituted or unsubstituted carbocyclyl, for example, cyclopropyl or cyclobutyl. 3d is substituted or unsubstituted cyclopropyl. In certain embodiments, R 3d Each instance of R is hydrogen, -F, -Br, -Cl, -I, -CH, -CF, -CHCHCl, cyclopropyl, or cyclobutyl. 3d is Me or Cl. In certain embodiments, R 3d is a substituted or unsubstituted heterocyclyl.
[0156] -X 1 -R 3b Various embodiments of As generally defined above, the group -X 1 R 3b Whereas, X 1 are independently -O-, -S- or -N(R X )-, where R X Each instance of R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group; 3b is hydrogen, -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 )2, -S(=O)2R C1 , -S(=O)2OR C1 , -P(=O)2R C1 , -P(=O)2OR C1 , -P(=O)(OR C1 )2, -P(=O)(R C1 )2, or -P(=O)(R C1 )(OR C1 ), where R C1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R C1 The groups may be joined to form a substituted or unsubstituted heterocyclic ring. 1 -R 3b It is broadly understood that the -X group can be in the alpha position (down) or the beta position (up). 1 -R 3b is alpha. In certain embodiments, the group -X 1 -R 3b is beta.
[0157] In certain embodiments, X 1 is —O—. In certain embodiments, X 1 is -S-. In certain embodiments, X 1 is -N(R X In certain embodiments, R X is alkyl. In certain embodiments, R X is Me, Et, or i-Pr. In certain embodiments, R X is H, i.e., X 1 is -NH-.
[0158] In certain embodiments, R 3b is hydrogen. For example, in certain embodiments, the group -X 1 R 3b is —OH. In certain embodiments, the group —X 1 R 3b is -SH. In certain embodiments, the group -X 1 R 3b is -NH2 or -NHR X is.
[0159] In certain embodiments, R 3b is -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 )2, -S(=O)2R C1 , -S(=O)2OR C1 , -P(=O)2R C1 , -P(=O)2OR C1 , -P(=O)(OR C1 )2, -P(=O)(R C1 )2, or -P(=O)(R C1 )(OR C1 )
[0160] In certain embodiments, R C1 At least one instance of R is hydrogen or a protecting group, i.e., an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, or a nitrogen protecting group when attached to a nitrogen atom. In certain embodiments, R C1 At least one instance of is hydrogen.
[0161] In certain embodiments, R C1 At least one example of is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. C1 C 1-6Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Includes, but is not limited to, alkyl (e.g., -CH2OCH3 and -CH2OCH2CH3).
[0162] In certain embodiments, R C1 At least one example of is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 It is alkenyl.
[0163] In certain embodiments, R C1 At least one example of is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 It is alkynyl.
[0164] In certain embodiments, R C1 At least one example of is a substituted or unsubstituted carbocyclyl, e.g., a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 It is a carbocyclyl.
[0165] In certain embodiments, R C1 At least one example of is a substituted or unsubstituted heterocyclyl, for example, a substituted or unsubstituted 3- to 6-membered heterocyclyl, a substituted or unsubstituted 3- to 4-membered heterocyclyl, a substituted or unsubstituted 4- to 5-membered heterocyclyl, or a substituted or unsubstituted 5- to 6-membered heterocyclyl.
[0166] In certain embodiments, R C1 At least one instance of is substituted or unsubstituted aryl, for example, substituted or unsubstituted phenyl.
[0167] In certain embodiments, R C1 At least one instance of is a substituted or unsubstituted heteroaryl, for example, an optionally substituted 5- to 6-membered heteroaryl.
[0168] In certain embodiments, two R C1 The groups are joined to form a substituted or unsubstituted heterocyclic ring, for example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperazinyl ring, or a substituted or unsubstituted morpholinyl ring.
[0169] In certain embodiments, R 3b is -C(=O)R C1 , -C(=O)OR C1 , -C(=O)N(R C1 )2 or -C(=O)N(OR C1 )(R C1 ), where R C1 is as defined herein.
[0170] In certain embodiments, R 3b is -C(=O)R C1 For example, R C1 is, for example, substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6). 3b is —C(═O)CH. In certain embodiments, R 3b is -C(=O)(CH2) m COH, where m is an integer between 2 and 5, inclusive. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5. In certain embodiments, R 3b is -C(=O)CHCHC(=O)OH.
[0171] In certain embodiments, R 3b is -C(=O)OR C1 For example, R C1 is, for example, substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6).
[0172] In certain embodiments, R 3b is -C(=O)SR C1 For example, R C1is, for example, substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6).
[0173] In certain embodiments, R 3b is -C(=O)N(R C1 )2, e.g., -C(=O)NH2 or -C(=O)NHR C1 where R C1 is, for example, substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6), or R 1 is -C(=O)N(R C1 )2, where the two R C1 The groups are joined to form a substituted or unsubstituted heterocyclic ring, for example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperazinyl ring, or a substituted or unsubstituted morpholinyl ring.
[0174] In certain embodiments, R 3b is -S(=O)2R C1 or -S(=O)2OR C1 where R C1is, for example, hydrogen, or substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6), or substituted or unsubstituted phenyl. 3b is -S(=O)2R C1 In certain embodiments, R 3b is -S(=O)2OR C1 , for example, -SO3H.
[0175] In certain embodiments, R 3b is -P(=O)2R C1 , -P(=O)2OR C1 , -P(=O)(OR C1 )2, -P(=O)(R C1 )2 or -P(=O)(R C1 )(OR C1 ) where each R C1 are, for example, independently hydrogen, substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6), or substituted or unsubstituted phenyl. In certain embodiments, R 3b is -P(=O)2R C1 In certain embodiments, R 1 is -P(=O)2OR C1 In certain embodiments, R 3b is -P(=O)(OR C1 )2. In certain embodiments, R 1 is -P(=O)(R C1)2. In certain embodiments, R 3b is -P(=O)(R C1 )(OR C1 )
[0176] Various embodiments in which Z is a group of formula (i) or (ii) In certain embodiments, Z is a group of formula (i): [ka]
[0177] In other embodiments, Z is a group of formula (ii): [ka]
[0178] As generally defined above, L 1 and L 2 is a bond (i.e., in other words, absent) or is substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted heteroC1-C6 alkylene, substituted or unsubstituted heteroC2-C6 alkenylene, or substituted or unsubstituted heteroC2-C6 alkynylene.
[0179] In certain embodiments, L 1 or L 2 is a bond.
[0180] In certain embodiments, L 1 or L 2 is substituted or unsubstituted C1-C6 alkylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C1-C4 alkylene. In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C1-C3 alkylene. 1or L 2 is a substituted or unsubstituted C1-C2 alkylene. 1 or L 2 is a substituted or unsubstituted C alkylene. In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C alkylene. 1 or L 2 is a substituted or unsubstituted C alkylene. 1 or L 2 is a substituted or unsubstituted C alkylene. In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C alkylene. 1 or L 2 is a substituted or unsubstituted C alkylene. 1 or L 2 is an alkylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo. In certain embodiments, L 1 or L 2 is -CH2-, -CHMe-, -CMe2-, -CH2-CH2-, -CF2-CH2-, -CH2-CMe2-, -CH2-CH2-CH2- or -CH2-CH2-CMe2-.
[0181] In certain embodiments, L 1 or L 2 is substituted or unsubstituted C-C alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C2-C5 alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C-C alkenylene. In certain embodiments, L 1 or L 2is substituted or unsubstituted C2-C3 alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C4 alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C5 alkenylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C6 alkenylene. In certain embodiments, L 1 or L 2 is an alkenylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
[0182] In certain embodiments, L 1 or L 2 is substituted or unsubstituted C2-C6 alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C2-C5 alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C2-C4 alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C2-C3 alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C alkynylene. In certain embodiments, L 1 or L 2is substituted or unsubstituted C4 alkynylene. In certain embodiments, L 1 is substituted or unsubstituted C5 alkynylene. In certain embodiments, L 1 or L 2 is substituted or unsubstituted C alkynylene. In certain embodiments, L 1 or L 2 is an alkynylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
[0183] Furthermore, in certain embodiments, L 1 or L 2 is a substituted or unsubstituted heterocyclic C 1-6 Alkylene, e.g., substituted or unsubstituted hetero C 1-2 Alkylene, substituted or unsubstituted hetero C 2-3 Alkylene, substituted or unsubstituted hetero C 3-4 Alkylene, substituted or unsubstituted hetero C 4-5 Alkylene or substituted or unsubstituted hetero C 5-6 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted heterocyclic C 2-6 Alkenylene, for example, substituted or unsubstituted hetero C 2-3 Alkenylene, substituted or unsubstituted hetero C 3-4 Alkenylene, substituted or unsubstituted hetero C 4-5 Alkenylene or substituted or unsubstituted hetero C 5-6 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted heterocyclic C 2-6 Alkynylene, for example, substituted or unsubstituted hetero C 2-3 Alkynylene, substituted or unsubstituted hetero C 3-4 Alkynylene, substituted or unsubstituted hetero C 4-5 Alkynylene or substituted or unsubstituted hetero C 5-6In any of the above examples, in certain embodiments, L 1 or L 2 is unsubstituted, or halo (e.g., fluoro) or substituted or unsubstituted C 1-6 It is a heteroalkylene, heteroalkenylene, or heteroalkynylene substituted with alkyl.
[0184] As generally defined above, R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N3, -NO2, -SCN, -CN, -OR A1 , -SR A1 , -N(R A1 )2, -N=NR A1 , -N=C(R A1 )2, -N(OR A1 )(R A1 ), -C(=O)R A1 , -C(=O)OR A1 , -C(=O)SR A1 , -C(=O)N(R A1 )2, -C(=O)N(OR A1 )(R A1 ), -OC(=O)R A1 , -OC(=O)OR A1 , -OC(=O)SR A1 , -OC(=O)N(R A1 )2, -NR A1 C(=O)R A1 , -NR A1 C(=O)OR A1 , -NR A1 C(=O)SR A1 , -NR A1 C(=O)N(R A1 )2, -SC(=O)R A2 , -SC(=O)OR A1 , -SC(=O)SR A1 , -SC(=O)N(R A1 )2, -OS(=O)2R A2 , -OS(=O)2ORA1 , -SS(=O)2R A2 , -SS(=O)2OR A1 , -S(=O)R A2 , -SO2R A2 , -NR A1 SO2R A2 , or -SO2N(R A1 )2, where R A1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R A1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R A2 is a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R A1 Groups and R A2 The groups are joined to form a substituted or unsubstituted heterocyclic ring.
[0185] In certain embodiments, R 1 is hydrogen.
[0186] In certain embodiments, R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. 1 is substituted or unsubstituted alkyl, e.g., Me, Et, or i-Pr. In certain embodiments, R 1 is substituted or unsubstituted alkenyl, for example, substituted or unsubstituted ethenyl or substituted or unsubstituted propenyl. 1 is a substituted or unsubstituted alkynyl.
[0187] In certain embodiments, R 1 is selected from substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl.
[0188] In certain embodiments, R 1 is substituted or unsubstituted aryl, for example, phenyl.
[0189] In certain embodiments, R 1 is a substituted or unsubstituted heteroaryl, for example, a substituted or unsubstituted heteroaryl selected from pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, quinazonyl, quinoxylinyl, naphthyridinyl, indolyl, indazolyl, benzimidazolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyridopyrimidinyl, or purinyl. In certain embodiments, the heteroaryl group is substituted with one or more groups selected from substituted or unsubstituted alkyl, haloalkyl, alkenyl, substituted or unsubstituted alkynyl, oxo, hydroxy, halo, alkoxy, -S-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -SO-alkyl, substituted or unsubstituted -SO-alkyl, substituted or unsubstituted -SO-aryl, substituted or unsubstituted -SO-aryl, substituted or unsubstituted -SO-heteroaryl, substituted or unsubstituted -SO-heteroaryl, amino, cyano, and acyl. 1 is imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, or tetrazolyl; each is unsubstituted or substituted with one or two groups independently selected from oxo, Me, F, Cl, —CN, and —CF. In certain embodiments, R1 is quinolinyl, isoquinolinyl, or purinyl; each is unsubstituted or substituted with one or two groups independently selected from oxo, Me, F, Cl, —CN, and —CF 3 .
[0190] In certain embodiments, R 1 -OR A1 In certain embodiments, R 1 is -O-quinolinyl, -O-isoquinolinyl, -O-purinyl, each of which is unsubstituted or substituted with one or two groups independently selected from Me, F, Cl, -CN, and -CF. In certain embodiments, R 1 is -OH or -O-CO-CH2-CH2-CO2H.
[0191] In certain embodiments, R 1 -SR A1 In certain embodiments, R 1 is -S-quinolinyl, -S-isoquinolinyl, or -S-purinyl, each of which is unsubstituted or substituted with one or two groups independently selected from Me, F, Cl, -CN, and -CF. In certain embodiments, R 1 is -SH.
[0192] In certain embodiments, R 1 is -OS(=O)2R A2 In certain embodiments, R 1 is -OS(=O)2OR A1 For example, —O—SO3H. In certain embodiments, R 1 is -SS(=O)2R A2 In certain embodiments, R 1 is -SS(=O)2OR A1 ;For example, -S-SO3H.
[0193] As generally defined above, R 20are independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 20 is hydrogen. In certain embodiments, R 20 is substituted or unsubstituted alkyl (e.g., —CH 3 ).
[0194] As generally defined above, R 23a and R 23b Each instance of is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form a substituted or unsubstituted C-C cycloalkyl. In certain embodiments, R 23a and R 23b Each instance of R is hydrogen. 23a and R 23b is halogen, e.g., fluoro, and R 23a and R 23b The other of R is hydrogen, halogen, or substituted or unsubstituted alkyl. 23a and R 23b Each instance of R is halogen, e.g., fluoro. 23a and R 23b Each instance of is independently substituted or unsubstituted alkyl. In certain embodiments, R 23a and R 23b Each of R is Me. 23a and R 23b is H. In certain embodiments, R 23a and R 23b is H; and the other is substituted or unsubstituted alkyl. In certain embodiments, R 23a and R 23b is H; and the other is Me or Et. In certain embodiments, R 23a and R 23b are joined together to form a substituted or unsubstituted C-C cycloalkyl. In certain embodiments, R23a and R 23b are joined together to form a substituted or unsubstituted cyclopropyl.
[0195] In certain embodiments, the group [ka] is the following formula: [ka]
[0196] As generally defined above, X 2 are independently -O-, -S- or -N(R X ), where R X Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group.
[0197] In certain embodiments, X 2 is —O—. In certain embodiments, X 2 is -S-. In certain embodiments, X 2 is -N(R X In certain embodiments, R X is alkyl. In certain embodiments, R X is Me, Et, or i-Pr. In certain embodiments, R X is hydrogen.
[0198] In certain embodiments, X 1 is -O- and X 2 is —O—. In certain embodiments, X 1 is -O- and X 2is -S-. In certain embodiments, X 1 is -O- and X 2 is -N(R X In certain embodiments, X 1 is -S- and X 2 is —O—. In certain embodiments, X 1 is -S- and X 2 is -S-. In certain embodiments, X 1 is -S- and X 2 is -N(R X In certain embodiments, X 1 is -N(R X )- and X 2 is —O—. In certain embodiments, X 1 is -N(R X )- and X 2 is -S-. In certain embodiments, X 1 is -N(R X )- and X 2 is -N(R X )-.
[0199] As generally defined above, R 24 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)R E1 , -C(=O)OR E1 , -C(=O)SR E1 , -C(=O)N(R E1 )2, -S(=O)2R E2 , -S(=O)2OR E1 , -P(=O)2R E2 , -P(=O)2OR E1 , -P(=O)(OR E1 )2, -P(=O)(R E2 )2, or -P(=O)(R E2 )(OR E1 )
[0200] In certain embodiments, R 24 is hydrogen.
[0201] In certain embodiments, R 24 is substituted or unsubstituted alkyl. In certain embodiments, R 24 is alkyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo and / or hydroxyl. In certain embodiments, R 24 is substituted or unsubstituted alkenyl. In certain embodiments, R 24 is substituted or unsubstituted alkynyl. In certain embodiments, R 24 is substituted or unsubstituted carbocyclyl. In certain embodiments, R 24 is substituted or unsubstituted heterocyclyl. In certain embodiments, R 24 is substituted or unsubstituted aryl. In certain embodiments, R 24 is a substituted or unsubstituted heteroaryl.
[0202] In certain embodiments, R 24 is -C(=O)R E1 For example, R 24 is -C(=O)(CH2) p COH, where p is an integer between 2 and 5, inclusive. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 4. In certain embodiments, p is 5. In certain embodiments, R 24 is -C(=O)OR E1 In certain embodiments, R 24 is -C(=O)SR E1 In certain embodiments, R 24 is -C(=O)N(R E1 )2. In certain embodiments, R 24 is -S(=O)2RE2 In certain embodiments, R 24 is -S(=O)2OR E1 For example, -SO3H. In certain embodiments, R 24 is -P(=O)2R E2 In certain embodiments, R 24 is -P(=O)2OR E1 In certain embodiments, R 24 is -P(=O)(OR E1 )2. In certain embodiments, R 24 is -P(=O)(R E2 )2. In certain embodiments, R 24 is -P(=O)(R E2 )(OR E1 )
[0203] As generally defined above, the subscript n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. Various embodiments in which Z is a group of formula (iii), (iv) or (v)
[0204] In certain embodiments, Z is a group of formula (iii), (iv), or (v): [ka]
[0205] In certain embodiments, L 3 is a substituted or unsubstituted C 1-6 Alkylene, for example, substituted or unsubstituted C 1-2 Alkylene, substituted or unsubstituted C 2-3 Alkylene, substituted or unsubstituted C 3-4 Alkylene, substituted or unsubstituted C 4-5 Alkylene or substituted or unsubstituted C 5-6 In certain embodiments, L3 is a substituted or unsubstituted C 2-6 Alkenylene, for example, substituted or unsubstituted C 2-3 Alkenylene, substituted or unsubstituted C 3-4 Alkenylene, substituted or unsubstituted C 4-5 Alkenylene or substituted or unsubstituted C 5-6 In certain embodiments, L 3 is a substituted or unsubstituted C 2-6 Alkynylene, for example, substituted or unsubstituted C 2-3 Alkynylene, substituted or unsubstituted C 3-4 Alkynylene, substituted or unsubstituted C 4-5 Alkynylene or substituted or unsubstituted C 5-6 In any of the above examples, in certain embodiments, L 3 is unsubstituted, or halo (e.g., fluoro), substituted or unsubstituted C 1-6 Alkyl and / or -OR Z5 and n is 0 or 1. The group is alkylene, alkenylene, or alkynylene, substituted with
[0206] Furthermore, in certain embodiments, L 3 is a substituted or unsubstituted heterocyclic C 1-6 Alkylene, e.g., substituted or unsubstituted hetero C 1-2 Alkylene, substituted or unsubstituted hetero C 2-3 Alkylene, substituted or unsubstituted hetero C 3-4 Alkylene, substituted or unsubstituted hetero C 4-5 Alkylene or substituted or unsubstituted hetero C 5-6 In certain embodiments, L 3 is a substituted or unsubstituted heterocyclic C 2-6 Alkenylene, for example, substituted or unsubstituted hetero C 2-3 Alkenylene, substituted or unsubstituted hetero C 3-4 Alkenylene, substituted or unsubstituted hetero C 4-5 Alkenylene or substituted or unsubstituted hetero C 5-6 In certain embodiments, L3 is a substituted or unsubstituted heterocyclic C 2-6 Alkynylene, for example, substituted or unsubstituted hetero C 2-3 Alkynylene, substituted or unsubstituted hetero C 3-4 Alkynylene, substituted or unsubstituted hetero C 4-5 Alkynylene or substituted or unsubstituted hetero C 5-6 In any of the above examples, in certain embodiments, L 3 is unsubstituted, or halo (e.g., fluoro), substituted or unsubstituted C 1-6 Alkyl and / or -OR Z5 and heteroalkylene, heteroalkenylene, or heteroalkynylene substituted with
[0207] In any of the above or below examples, in certain embodiments, at least one R Z5 is hydrogen.
[0208] In any of the above or below examples, in certain embodiments, R Z5 At least one example of is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. Z5 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups.1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Includes, but is not limited to, alkyl (e.g., -CH2OCH3 and -CH2OCH2CH3).
[0209] In any of the above or below examples, in certain embodiments, R Z5 At least one example of is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 It is alkenyl.
[0210] In any of the above or below examples, in certain embodiments, R Z5 At least one example of is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 It is alkynyl.
[0211] In any of the above or below examples, in certain embodiments, R Z5 At least one example of is a substituted or unsubstituted carbocyclyl, e.g., a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C5-6 It is a carbocyclyl.
[0212] In any of the above or below examples, in certain embodiments, R Z5 At least one example of is a substituted or unsubstituted heterocyclyl, for example, a substituted or unsubstituted 3- to 6-membered heterocyclyl, a substituted or unsubstituted 3- to 4-membered heterocyclyl, a substituted or unsubstituted 4- to 5-membered heterocyclyl, or a substituted or unsubstituted 5- to 6-membered heterocyclyl.
[0213] In any of the above or below examples, in certain embodiments, R Z5 At least one instance of is substituted or unsubstituted aryl, for example, substituted or unsubstituted phenyl.
[0214] In any of the above or below examples, in certain embodiments, R Z5 At least one instance of is a substituted or unsubstituted heteroaryl, for example, an optionally substituted 5- to 6-membered heteroaryl.
[0215] In any of the above or below examples, in certain embodiments, R Z5 is a protecting group, e.g., an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, or a nitrogen protecting group when attached to a nitrogen atom.
[0216] The Two R's Z5 In certain embodiments where R is attached to a nitrogen atom, the two R Z5 The groups are joined to form a substituted or unsubstituted heterocyclic ring, for example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperazinyl ring, or a substituted or unsubstituted morpholinyl ring.
[0217] Furthermore, in certain embodiments in any of the above or below examples, R Z6 Each instance of is independently hydrogen, substituted or unsubstituted alkyl, or two R Z6The group is connected to C 3-6 Forms a carbocyclic ring.
[0218] In certain embodiments, R Z6 At least one instance of is hydrogen.
[0219] In certain embodiments, R Z6 At least one example of is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. Z4 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Includes, but is not limited to, alkyl (e.g., -CH2OCH3 and -CH2OCH2CH3).
[0220] In certain embodiments, two R Z6 The group is connected to C 3-6It forms a carbocyclic ring, for example a substituted or unsubstituted cyclopropyl ring, a substituted or unsubstituted cyclobutyl ring, a substituted or unsubstituted cyclopentyl ring or a substituted or unsubstituted cyclohexyl ring.
[0221] In certain embodiments, R Z4 is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. Z4 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Includes, but is not limited to, alkyl (e.g., -CH2OCH3 and -CH2OCH2CH3).
[0222] In certain embodiments, R Z4 is a substituted or unsubstituted alkenyl, for example, a substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 It is alkenyl.
[0223] In certain embodiments, R Z4 is a substituted or unsubstituted alkynyl, for example, a substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 It is alkynyl.
[0224] In certain embodiments, R Z4 is a substituted or unsubstituted carbocyclyl, for example, a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 It is a carbocyclyl.
[0225] In certain embodiments, R Z4 is a substituted or unsubstituted heterocyclyl, for example, a substituted or unsubstituted 3- to 6-membered heterocyclyl, a substituted or unsubstituted 3- to 4-membered heterocyclyl, a substituted or unsubstituted 4- to 5-membered heterocyclyl, or a substituted or unsubstituted 5- to 6-membered heterocyclyl.
[0226] In certain embodiments, R Z4 is substituted or unsubstituted aryl, for example, substituted or unsubstituted phenyl.
[0227] In certain embodiments, R Z4 is a substituted or unsubstituted heteroaryl, for example, an optionally substituted 5- to 6-membered heteroaryl.
[0228] In certain embodiments, R Z4-OR Z5 where R Z5 is as defined herein, for example, R Z5 is hydrogen, methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6).
[0229] In certain embodiments, R Z4 -SR Z5 where R Z5 is as defined herein, for example, R Z5 is hydrogen, methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6).
[0230] In certain embodiments, R Z4 is -N(R Z5 )2, for example, R Z4 is -NH2 or -NHR Z5 where R Z5 is as defined herein, for example, R Z5 is hydrogen, methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) or n-hexyl (C6), or R Z4 is -N(R Z5 )2, where the two RZ5 The groups are joined to form a substituted or unsubstituted heterocyclic ring, for example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperazinyl ring, or a substituted or unsubstituted morpholinyl ring.
[0231] Specific L 3 Alkylene groups are contemplated herein. For example, in certain embodiments, L 3 is an alkylene group of the formula: [ka] where p is 1, 2, or 3; R Z7 and R Z8 Each instance of is independently hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
[0232] Also, specific L 3 Alkenylene groups are contemplated herein. For example, in certain embodiments, L 3 is an alkenylene group of the formula: [ka] wherein q is 0, 1, or 2; R Z7 and R Z8 Each instance of is independently hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2.
[0233] Also, specific L 3 Heteroalkylene groups are contemplated herein, for example, in certain embodiments, L 3is a heteroalkylene group of the formula: [ka] wherein w is 0 or 1 and p is 1, 2, or 3, or w is 1 and p is 0, 1, 2, or 3; R Z7 and R Z8 Each instance of is independently hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 is.
[0234] In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, w is 0. In certain embodiments, w is 1. In certain embodiments, w is 0 and p is 1. In certain embodiments, w is 0 and p is 2. In certain embodiments, w is 0 and p is 3. In certain embodiments, w is 1 and p is 1. In certain embodiments, w is 1 and p is 2. In certain embodiments, w is 1 and p is 3.
[0235] For example, in certain embodiments where w is 0, L 3 Heteroalkylene groups are provided: [ka] In the formula, p and R Z8 is as defined herein.
[0236] In certain embodiments where w is 1, L 3 Heteroalkylene groups are provided: [ka] In the formula, p, R 27 and R Z8 is as defined herein.
[0237] In certain embodiments, R Z7 At least one instance of is hydrogen. In any of the above instances, in certain embodiments, R Z7 At least one instance of is halo, e.g., fluoro. In any of the above instances, in certain embodiments, R Z7 At least one instance of 1-6 Alkyl, e.g., substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. Z7 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6In any of the above examples, in certain embodiments, R Z7 At least one example of is -CH, -CF, -CHCH(Et), or -CH(CH)(iPr). In any of the above examples, in certain embodiments, R Z7 At least one instance of -OR Z5 , for example, —OH.
[0238] In certain embodiments, R Z8 At least one instance of is hydrogen. In any of the above instances, in certain embodiments, R Z8 At least one instance of is halo, e.g., fluoro. In any of the above instances, in certain embodiments, R Z8 At least one instance of 1-6 Alkyl, e.g., substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. Z8 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 In any of the above examples, in certain embodiments, R Z8 At least one example of is -CH, -CF, -CHCH(Et), or -CH(CH)(iPr). In any of the above examples, in certain embodiments, R Z8 At least one instance of -OR Z5 , for example, —OH.
[0239] Exemplary L 3 Alkylene groups include, but are not limited to: [ka]
[0240] Exemplary L 3 Alkenylene groups include, but are not limited to: [ka]
[0241] Exemplary L 3 Heteroalkylene groups include, but are not limited to: [ka]
[0242] In certain embodiments, the group [ka] (In the formula, L 3 is an alkylene or heteroalkylene group) is of the formula: [ka] [ka]
[0243] In certain embodiments, the group [ka] (Wherein, Y is —O—, and L 3 is an alkylene or heteroalkylene group) is of the formula: [ka] [ka]
[0244] In certain embodiments, the group [ka] (Wherein, Y is —NH—, and L 3 is an alkylene or heteroalkylene group) is of the formula: [ka]
[0245] In certain embodiments, the group [ka] (Wherein, Y is —O—, and L 3 is an alkylene or heteroalkylene group) is of the formula: [ka]
[0246] In certain embodiments, the group [ka] (Wherein, Y is —NH—, and L 3 is an alkylene or heteroalkylene group) is of the formula: [ka]
[0247] R 2 , R 11a and R 11b Various embodiments of As generally defined above, R 2 , R 11a and R 11b Each instance of is independently selected from H, —OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —N, —NO, —SCN, —CN, —OR B1 , -SR B1 , -N(R B1 )2, -N=NR B1 , -N=C(R B1 )2, -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 )2, -C(=O)N(OR B1 )(R B1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 )2, -NR B1 C(=O)R B1 , -NRB1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 )2, -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 )2, -OS(=O)2R B2 , -OS(=O)2OR B1 , -SS(=O)2R B2 , -SS(=O)2OR B1 , -S(=O)R B2 , -SO2R B2 , -NR B1 SO2R B2 , or -SO2N(R B1 )2 and / or R 11a and R 11b together form an oxo (=O) group.
[0248] In certain embodiments, R 2 is H. In certain embodiments, R 2 is substituted or unsubstituted alkyl. In certain embodiments, R 2 is substituted or unsubstituted alkenyl. In certain embodiments, R 2 is substituted or unsubstituted alkynyl. In certain embodiments, R 2 -OR B1 In certain embodiments, R 2 -SR B1 In certain embodiments, R 2 is -N(R B1 )2. In certain embodiments, R 2 is H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -OR B1 , -SR B1 or -N(R B1 )2. In certain embodiments, R 2is F, Cl, Me, Et, n-Pr, methoxy, ethoxy, propoxy, butoxy, ethynyl, hydroxybutynyl, methoxypropynyl, chloroethynyl, or cyclopropynyl. 2 is CF, amino, or dimethylamino. In certain embodiments, R 2 is a non-hydrogen group at the alpha position. In certain embodiments, R 2 is a non-hydrogen group in the beta position.
[0249] In certain embodiments, R 11a and R 11b Each instance of R is hydrogen. 11a and R 11b One of R is hydrogen. 11a and R 11b is hydrogen; and the other is -OR B1 , -SR B1 or -N(R B1 )2. In certain embodiments, R 11a and R 11b is H; and the other is -OH, -OMe, amino, or dialkylamino. 11b is a non-hydrogen group, and R 11a is hydrogen. In certain embodiments, R 11a is a non-hydrogen group, and R 11b is hydrogen.
[0250] In certain embodiments, R 11a and R 11b together form an oxo group. R 4a , R 4b , R 6 , R 7a , R 7b , R 14 , R 17 , R 18 and R 19 Various embodiments of
[0251] As generally defined above, R 4a , R 4b , R 7a and R 7b Each instance of is independently selected from hydrogen, —OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —N, —NO, —SCN, —CN, —OR B1 , -SR B1 , -N(R B1 )2, -N=NR B1 , -N=C(R B1 )2, -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 )2, -C(=O)N(OR B1 )(R B1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 )2, -NR B1 C(=O)R B1 , -NR B1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 )2, -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 )2, -OS(=O)2R B2 , -OS(=O)2OR B1 , -SS(=O)2R B2 , -SS(=O)2OR B1 , -S(=O)R B2 , -SO2R B2 , -NR B1 SO2R B2, or -SO2N(R B1 )2, where R B1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B1 groups are joined to form a substituted or unsubstituted heterocyclic ring; R B2 is a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R B1 Groups and R B2 groups may be joined to form a substituted or unsubstituted heterocyclic ring; or optionally, R 4a and R 4b and / or R 7a and R 7b taken together form an oxo (=O) group.
[0252] In certain embodiments, R 4a and R 4b Each instance of R is hydrogen. 4a and R 4b One of R is hydrogen. 4a and R 4b is hydrogen; and the other is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, R 4a and R 4b is hydrogen; and the other is Me, Et, ethenyl, ethynyl, propenyl, or propynyl. 4a and R 4bEach of R is independently substituted or unsubstituted alkyl. 4a and R 4b Each of is Me.
[0253] In certain embodiments, R 7a and R 7b Each instance of is hydrogen.
[0254] As generally defined above, R 6a and R 6b each is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; [ka] represents a single bond or a double bond, provided that when a double bond is present in ring B, R 6a or R 6b When one of the groups is absent and a single bond is present in ring B, the hydrogen at C5 is in the alpha or beta position.
[0255] [ka] In certain embodiments, R represents a single bond. 6a and R 6b Each instance of R is hydrogen. 6a and R 6b Each instance of is halo, for example, fluoro.
[0256] [ka] In certain embodiments, R represents a single bond. 6a is hydrogen and R 6bis halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. 6a is hydrogen and R 6b is halo (e.g., fluoro). In certain embodiments, R 6a is hydrogen and R 6b is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 alkyl, for example, methyl, ethyl, propyl, or isopropyl. In certain embodiments, R 6a is hydrogen and R 6b is substituted or unsubstituted alkenyl. In certain embodiments, R 6a is hydrogen and R 6b is a substituted or unsubstituted alkynyl.
[0257] [ka] In certain embodiments, R represents a single bond. 6b is hydrogen and R 6a is halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. 6b is hydrogen and R 6a is halo (e.g., fluoro). In certain embodiments, R 6b is hydrogen and R 6a is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 alkyl, for example, methyl, ethyl, propyl, or isopropyl. In certain embodiments, R 6b is hydrogen and R 6a is substituted or unsubstituted alkenyl. In certain embodiments, R 6b is hydrogen and R 6a is a substituted or unsubstituted alkynyl.
[0258] [ka] In certain embodiments, R represents a double bond. 6a is hydrogen. [ka] In certain embodiments, R represents a double bond. 6a is halo, for example fluoro. [ka] In certain embodiments, R represents a double bond. 6a is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl, for example, methyl, ethyl, propyl or isopropyl. [ka] In certain embodiments, R represents a double bond.6a is a substituted or unsubstituted alkenyl. [ka] In certain embodiments, R represents a double bond. 6a is a substituted or unsubstituted alkynyl.
[0259] As generally defined above, R 17 is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -OR D1 In certain embodiments, R 17 is hydrogen. In certain embodiments, R 17 is halo. In certain embodiments, R 17 is substituted or unsubstituted alkyl. In certain embodiments, R 17 is substituted or unsubstituted alkenyl. In certain embodiments, R 17 is substituted or unsubstituted alkynyl. In certain embodiments, R 17 is substituted or unsubstituted carbocyclyl. In certain embodiments, R 17 is substituted or unsubstituted heterocyclyl. In certain embodiments, R 17 is substituted or unsubstituted aryl. In certain embodiments, R 17 is substituted or unsubstituted heteroaryl. In certain embodiments, R 17 -OR D1 (e.g., —OH).
[0260] As generally defined above, R 14 is H or substituted or unsubstituted alkyl. In certain embodiments, R 14 is H. In certain embodiments, R 14is substituted or unsubstituted alkyl (e.g., —CH 3 ).
[0261] As generally defined above, R 18 are independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 18 is hydrogen. In certain embodiments, R 18 is substituted or unsubstituted alkyl (e.g., —CH 3 ).
[0262] As generally defined above, R 19 are independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 19 is hydrogen. In certain embodiments, R 19 is substituted or unsubstituted alkyl (e.g., —CH 3 ).
[0263] In certain embodiments, R 14 is hydrogen and R 18 is -CH3 and R 19 is -CH3.
[0264] In certain embodiments, R 14 is hydrogen and R 18 is -CH3 and R 19 is hydrogen.
[0265] Further embodiments of formula (I) Various combinations of the above embodiments are further contemplated herein. For example, in certain embodiments, the compound of formula (I) may be a compound of formula (Iw): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3bis hydrogen. In certain embodiments, the group -X 1 R 3b is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl.
[0266] In certain embodiments, the compound of formula (I) is a compound of formula (Ix): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the —OH group at the C3 position is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl.
[0267] In certain embodiments, the compound of formula (I) is a compound of formula (Iy): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the —OH group at the C3 position is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.
[0268] In certain embodiments, the compound of formula (I) is a compound of formula (Iz): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the —OH group at the C3 position is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.
[0269] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-a1), (I-a2) or (I-a3): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, the group -OR at the C3 position 3b is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.
[0270] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-b1), (I-b2) or (I-b3): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, R 3ais hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.
[0271] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-c1), (I-c2) or (I-c3): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 In certain embodiments, R 6a and R 6b and R are both hydrogen. 6ais halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.
[0272] In certain embodiments, the compound is a compound of formula (Id): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, the group -X 1 R 3b is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6band R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, each R Z6 is independently hydrogen or methyl.
[0273] In certain embodiments, the compound is a compound of formula (Ie): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, each R Z6 is independently hydrogen or methyl.
[0274] In certain embodiments, the compound is a compound of formula (If): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, the group -X 1 R 3b is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, each R Z6 is independently hydrogen or methyl. In certain embodiments, R Z5 is hydrogen or methyl.
[0275] In certain embodiments, the compound is a compound of formula (Ig): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, each R Z6 is independently hydrogen or methyl. In certain embodiments, R Z5 is hydrogen or methyl.
[0276] In certain embodiments, the compound is a compound of formula (Ih): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3b is hydrogen. In certain embodiments, the group -X 1 R 3b is beta. In certain embodiments, R 3ais hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, R Z6 is isopropyl.
[0277] In certain embodiments, the compound is a compound of formula (Ii): [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 is. [ka] In certain embodiments, R represents a single bond. 5 is alpha (bottom) and R 6a is hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b and R are both hydrogen. 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen. In certain embodiments, R 6a and R 6b and R are both halo, e.g., fluoro. 19 is methyl. In certain embodiments, R Z6 is isopropyl.
[0278] Further embodiments of formula (I) include compounds of the formula: [ka] [ka] [ka] [ka] [ka]
[0279] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0280] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0281] In certain embodiments, the compound is the following compound: [ka] [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0282] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0283] In certain embodiments, the compound is the following compound: [ka] [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0284] In certain embodiments, the compound is the following compound: [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0285] In certain embodiments, the compound is the following compound: [ka] or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[0286] In certain embodiments, the compound of formula (I) is a compound of formula (Iq) [ka] and pharmaceutically acceptable salts thereof; During the ceremony: R 1 is substituted or unsubstituted aliphatic (alphatic); R 2 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted cyclopropyl or -OR A2 where R A2 is hydrogen or substituted or unsubstituted alkyl; R 3a is hydrogen or -OR A3 where R A3 is hydrogen or substituted or unsubstituted alkyl, and R 3b is hydrogen; or R 3a and R 3b together form an oxo (=O) group; R 4 is hydrogen, substituted or unsubstituted alkyl, or halogen; X is -C(R X )2- or -O-, where R X is hydrogen or fluorine, or one R X Groups and R 5b come together to form a double bond; R 5a and R 5b Each instance of is independently hydrogen or fluorine; R 6a is a non-hydrogen radical selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl groups, wherein the non-hydrogen radical is optionally substituted with fluorine; R 6b is hydrogen, or a substituted or unsubstituted alkyl group optionally substituted with fluorine; [ka] represents a single or double bond, provided that if a single bond is present, the hydrogen at C5 is in the alpha configuration; Additionally, however: (1)R X , R 5a and R 5b at least one of is fluorine; or (2)R 6a and R 6b at least one of is a non-hydrogen group substituted with fluorine; or (3)R 6a is a non-hydrogen group containing 2 to 10 carbon atoms.
[0287] In certain embodiments, the compounds of the invention are pharmaceutically acceptable salts.
[0288] As broadly described herein, compounds of formula (Iq) in which the hydrogen at C5 is provided in the beta configuration exhibit reduced NMDA potentiation compared to compounds in which the hydrogen at C5 is alpha or a double bond is present at C5-C6. Thus, compounds of formula (Iq) are compounds of formulas (I-qA) and (I-qB): [ka] and pharmaceutically acceptable salts thereof.
[0289] The group R of the compound of formula (Iq) 1 As generally defined herein, R 1 is a substituted or unsubstituted aliphatic, ie, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted carbocyclyl.
[0290] In certain embodiments, R1 is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. 1 C 1-6 Alkyl groups include substituted or unsubstituted methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups. 1-6 alkyl (e.g., -CF3, -CH2F, -CHF2, difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), C substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups 1-6 C substituted with alkyl (e.g., -CH2Cl, -CHCl2) and alkoxy groups 1-6 Examples include, but are not limited to, alkyl (e.g., —CH2OCH3, —CH2OCH2CH3, —CH2O-cyclopropyl). In certain embodiments, R 1 is a substituted alkyl, for example, R 1 is haloalkyl, alkoxyalkyl, or aminoalkyl. In certain embodiments, R 1 is Me, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoro-1,1-dimethyl-ethyl, methoxymethyl, methoxyethyl or ethoxymethyl.
[0291] In certain embodiments, R 1 is the unsubstituted C 1-3 alkyl, e.g., R 1 is -CH3, -CH2CH3, -CH2CH2CH3 or -CH2CH2CH2CH3.
[0292] In certain embodiments, R 1 is alkyl substituted with one or more fluorine atoms; for example, R 1 is -CH2F, -CHF2 or -CF3.
[0293] In certain embodiments, R 1 -OR -One or more A1 alkyl substituted with a group, where R A1 is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 1 is -CH2OR A1 For example, where R A1 is hydrogen, -CH3, -CH2CH3 or -CH2CH2CH3.
[0294] In certain embodiments, R 1 is a substituted or unsubstituted alkenyl, for example, a substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 In certain embodiments, R is alkenyl. 1 is ethenyl (C2), propenyl (C3), or butenyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R 1is ethenyl, propenyl, or butenyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxy. In certain embodiments, R 1 is ethenyl.
[0295] In certain embodiments, R 1 is a substituted or unsubstituted alkynyl, for example, a substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 alkynyl. Exemplary substituted or unsubstituted R 1 Alkynyl groups include, but are not limited to, ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl (e.g., CF), alkoxyalkyl, cycloalkyl (e.g., cyclopropyl or cyclobutyl), or hydroxyl. In certain embodiments, R 1 is selected from the group consisting of trifluoroethynyl, cyclopropylethynyl, cyclobutylethynyl, and propynyl, fluoropropynyl, and chloroethynyl. 1 is ethynyl (C2), propynyl (C3), or butynyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl. In certain embodiments, R 1 is ethynyl (C2), propynyl (C3), or butynyl (C4) substituted with a substituted phenyl. In certain embodiments, the phenyl substituent is further substituted with one or more substituents selected from the group consisting of halo, alkyl, trifluoroalkyl, alkoxy, acyl, amino, or amido. In certain embodiments, R 1is ethynyl (C2), propynyl (C3) or butynyl (C4) substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl.
[0296] In certain embodiments, R 1 is ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R 1 is ethynyl or propynyl substituted with substituted or unsubstituted aryl. In certain embodiments, R 1 is ethynyl or propynyl substituted with unsubstituted phenyl or phenyl substituted with halo, alkyl, alkoxy, haloalkyl, trihaloalkyl, or acyl. In certain embodiments, R 1 is ethynyl or propynyl substituted with a substituted or unsubstituted carbocyclyl. 3a is ethynyl or propynyl, substituted or unsubstituted with cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 1 is ethynyl or propynyl substituted with substituted or unsubstituted heteroaryl. 1 is substituted or unsubstituted, pyridinyl or pyrimidinyl, ethynyl or propynyl. In certain embodiments, R 1 is ethynyl or propynyl substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl. In certain embodiments, R 1 is ethynyl or propynyl substituted with substituted or unsubstituted heterocyclyl.1 is ethynyl or propynyl substituted with substituted or unsubstituted pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In certain embodiments, R 1 is propynyl or butynyl substituted with hydroxyl or alkoxy. In certain embodiments, R 1 is propynyl or butynyl substituted with methoxy or ethoxy. 1 is ethynyl or propynyl substituted with chloro. In certain embodiments, R 1 is ethynyl or propynyl substituted with trifluoromethyl.
[0297] In certain embodiments, R 1 is a substituted or unsubstituted carbocyclyl, for example, a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 In certain embodiments, R 1 is substituted or unsubstituted cyclopropyl or substituted or unsubstituted cyclobutyl. The group R of the compound of formula (Iq) 2 , R 3a , R 3b and R 4
[0298] As generally defined herein, R 2 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted cyclopropyl or -OR A2 where R A2 is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen. In certain embodiments, R 2 is halogen, for example, fluoro, chloro, bromo, or iodo. In certain embodiments, R2 is fluoro or chloro. In certain embodiments, R 2 is a substituted or unsubstituted C 1-6 Alkyl, e.g., substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 In certain embodiments, R 2 is -CH3, -CH2CH3, -CH2CH2CH3 or cyclopropyl. 2 -OR A2 In certain embodiments, R A2 is hydrogen. In certain embodiments, R A2 is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 In certain embodiments, R A2 is hydrogen, -CH3, -CH2CH3 or -CH2CH2CH3, i.e. a group R of formula -OH, -OCH3, -OCH2CH3 or -OCH2CH2CH3 2 In certain embodiments, R 2 is a non-hydrogen substituent in the alpha configuration. 2 is a non-hydrogen substituent in the beta configuration.
[0299] As generally defined herein, R 3a is hydrogen or -OR A3 where R A3 is hydrogen or substituted or unsubstituted alkyl, and R 3b is hydrogen; or R3a and R 3b together form an oxo (=O) group.
[0300] In certain embodiments, R 3a and R 3b are both hydrogen.
[0301] In certain embodiments, R 3a and R 3b together form an oxo (=O) group.
[0302] In certain embodiments, R 3a -OR A3 and R 3b is hydrogen. 3a -OR A3 In certain embodiments, R 3a is in the alpha or beta configuration. 3a -OR A3 In certain embodiments, R 3a is the alpha configuration. R 3a -OR A3 In certain embodiments, R 3a is in the beta configuration. In certain embodiments, R A3 is hydrogen. In certain embodiments, R A3 is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 In certain embodiments, R A3 is hydrogen, -CH3, -CH2CH3 or -CH2CH2CH3, i.e. a group R of formula -OH, -OCH3, -OCH2CH3 or -OCH2CH2CH3 3a This provides:
[0303] As generally defined herein, R 4 is hydrogen, substituted or unsubstituted alkyl, or halogen. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halogen, e.g., fluoro. In certain embodiments, R 4 is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 In certain embodiments, R 4 is C alkyl, e.g., —CH or —CF. In certain embodiments, R 4 is hydrogen, -CH3, or -F. [ka] In certain embodiments, R represents a single bond. 4 is a non-hydrogen substituent in the alpha configuration. [ka] In certain embodiments, R represents a single bond. 4 is a non-hydrogen substituent in the beta configuration.
[0304] The groups X, R of the compound of formula (Iq) 5a , R 5b , R 6a and R 6b As generally defined herein, X is —C(R X )2- or -O-, where R X is hydrogen or fluorine, or one RX Groups and R 5b together form a double bond; R 5a and R 5b are each independently hydrogen or fluorine; R 6a is a non-hydrogen radical selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl groups, wherein the non-hydrogen radical is optionally substituted with fluorine; R 6b is hydrogen, or a substituted or unsubstituted alkyl group optionally substituted with fluorine; provided that: (1) R X , R 5a and R 5b at least one of R is fluorine; or 6a and R 6b at least one of R is a non-hydrogen group substituted with fluorine; or (3) R 6a is a non-hydrogen group containing 2 to 10 carbon atoms.
[0305] In certain embodiments, X is -O-. In certain embodiments, X is -CH2-. In certain embodiments, X is -CF2-.
[0306] In certain embodiments, R 5a and R 5b At least one of R is hydrogen. 5a and R 5b At least one of R is fluorine. 5a and R 5b and R are both hydrogen. 5a and R 5b and R are both fluorine. X and R 5b together form a double bond, for example a cis or trans double bond.
[0307] In certain embodiments, R 6a is a non-hydrogen group as described herein that is not substituted with fluorine. In certain embodiments, R 6a is substituted or unsubstituted alkyl (e.g., -CH, -CHCH, -CH(CH)), substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted carbocyclyl (e.g., isopropanol). 6a is a non-hydrogen group as described herein substituted with fluorine.
[0308] In certain embodiments, R 6a is a non-hydrogen group as described herein, and R 6b is hydrogen. In certain embodiments, R 6a is a non-hydrogen group as described herein, and R 6b is a substituted or unsubstituted alkyl group optionally substituted with fluorine. In certain embodiments, R 6b is an alkyl group that is not substituted with fluorine. In certain embodiments, R 6a is a fluorine-substituted alkyl group.
[0309] In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is a substituted or unsubstituted alkyl optionally substituted with fluorine, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 In certain embodiments, R 6b is C1 alkyl optionally substituted with fluorine, for example, -CH3 or -CF3.
[0310] In certain embodiments, R 6a is a substituted or unsubstituted alkyl, for example, a substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is alkyl. 6a C 1-6 Alkyl groups include, but are not limited to, substituted or unsubstituted methyl (C1), substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), substituted or unsubstituted isopropyl (C3), substituted or unsubstituted n-butyl (C4), substituted or unsubstituted tert-butyl (C4), substituted or unsubstituted sec-butyl (C4), substituted or unsubstituted iso-butyl (C4), substituted or unsubstituted n-pentyl (C5), substituted or unsubstituted 3-pentanyl (C5), substituted or unsubstituted amyl (C5), substituted or unsubstituted neopentyl (C5), substituted or unsubstituted 3-methyl-2-butanyl (C5), substituted or unsubstituted tertiary amyl (C5), and substituted or unsubstituted n-hexyl (C6). In certain embodiments, R 6a is alkyl, as described above, substituted with one or more fluorines, e.g., 1, 2, 3, 4 or more fluorines. In certain embodiments, R 6a is —CF, —CHF, —CHF, difluoroethyl, or 2,2,2-trifluoro-1,1-dimethyl-ethyl). 6a -OR -One or more A6 alkyl, as described above, substituted with a group, where R A6 is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2ORA6 , for example, -CH2OCH3, -CH2CH2OCH3 or -CH2CH2CH2OCH3.
[0311] In certain embodiments, R 6a is a substituted or unsubstituted alkenyl optionally substituted with fluorine, e.g., a substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 In certain embodiments, R is alkenyl. 6a is a substituted or unsubstituted vinyl (C2) or a substituted or unsubstituted allyl (C3).
[0312] In certain embodiments, R 6a is a substituted or unsubstituted alkynyl optionally substituted with fluorine, e.g., a substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 In certain embodiments, R 6a is a substituted or unsubstituted ethynyl (C2) or a substituted or unsubstituted propargyl (C3).
[0313] In certain embodiments, R 6a is a substituted or unsubstituted carbocyclyl optionally substituted with fluorine, e.g., a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl.
[0314] In certain embodiments, R 6a is a substituted or unsubstituted heterocyclyl optionally substituted with fluorine, e.g., a substituted or unsubstituted C 3-6 Heterocyclyl, substituted or unsubstituted C 3-4 Heterocyclyl, substituted or unsubstituted C 4-5 Heterocyclyl or substituted or unsubstituted C 5-6 It is a heterocyclyl.
[0315] In certain embodiments, R 6a is a substituted or unsubstituted aryl, for example, a substituted or unsubstituted phenyl, optionally substituted with fluorine.
[0316] In certain embodiments, R 6a is a substituted or unsubstituted heteroaryl, for example an optionally substituted 5-6 membered heteroaryl, optionally substituted with fluorine.
[0317] In certain embodiments, R 6a is a non-hydrogen group containing from 2 to 10 carbon atoms, e.g., from 2 to 9, from 2 to 8, from 2 to 7, from 2 to 6, from 2 to 5, from 2 to 4, or from 2 to 3 carbon atoms. For example, in certain embodiments, R 6a is a substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 2-3 It is alkynyl or substituted or unsubstituted C3 carbocyclyl.
[0318] In certain embodiments, R X , R 5a and R 5b at least one of R is fluorine; or R 6a and R 6b at least one of R is a non-hydrogen group substituted with fluorine; 6a is a substituted or unsubstituted C 1-3Alkyl, substituted or unsubstituted C 1-3 Alkenyl, substituted or unsubstituted C 1-3 It is alkynyl or substituted or unsubstituted C3 carbocyclyl.
[0319] In certain embodiments, R 6a and R 6b are the same group. In certain embodiments, R 6a and R 6b are different groups, and R 6a The carbon attached to R is in the (S) or (R) configuration. 6a The carbon attached to R is in the (S) configuration. 6a The carbon attached to is in the (R) configuration. 6a is -CF3, and R 6b is hydrogen or C 1-4 In certain embodiments, R 6a is a non-hydrogen group substituted with fluorine, and R 6b is -CH3. In certain embodiments, R 6a -OR -One or more A6 group, where R A6 is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 6a is a substituted or unsubstituted C 2-4 Alkyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 2-3 alkynyl or substituted or unsubstituted C3 carbocyclyl, and R 6b is -CH3. In certain embodiments, R 6a is the unsubstituted C 2-4 Alkyl, unsubstituted C 2-3 Alkenyl or unsubstituted C 2-3 alkynyl or unsubstituted C3 carbocyclyl, and R 6b is -CH3. In certain embodiments, R 6a is a non-hydrogen group substituted with fluorine, and R 6bis -CH3.
[0320] Various combinations of certain embodiments Various combinations of certain embodiments are further contemplated herein.
[0321] For example, X is -CH2- and R 5a and R 5b are both hydrogen, the compound of formula (I-qa): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6a The carbon attached to is in the (R) configuration. 6a is methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6a is substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6ais substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 1 is -CH3 or -CH2CH3. In certain embodiments, R 2 is hydrogen, —OH, —OCH, —OCHCH, —OCHCH, —CH, —CHCH, —CHCH, cyclopropyl, fluoro, or chloro. 2 is a non-hydrogen substituent in the alpha configuration. 2 is a non-hydrogen substituent in the beta configuration. 3a and R 3b and R are both hydrogen. 3a and R 3b taken together form =O (oxo). In certain embodiments, R 4 is hydrogen.
[0322] X is -CH2- and R 5a and R 5b are both fluorine, in a compound of formula (I-qb): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6a The carbon attached to is in the (R) configuration. 6a is methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6a is substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6a is substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 1 is -CH3 or -CH2CH3. In certain embodiments, R 2 is hydrogen, —OH, —OCH, —OCHCH, —OCHCH, —CH, —CHCH, —CHCH, cyclopropyl, fluoro, or chloro. 2 is a non-hydrogen substituent in the alpha configuration. 2 is a non-hydrogen substituent in the beta configuration. 3a and R 3b and R are both hydrogen. 3a and R 3b taken together form =O (oxo). In certain embodiments, R 4 is hydrogen.
[0323] X is -C(R X )2- and one R X Groups and R 5b together form a trans double bond, compounds of formula (I-qc): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6aThe carbon attached to is in the (R) configuration. 6a is methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6a is substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6a is substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 1 is -CH3 or -CH2CH3. In certain embodiments, R 2 is hydrogen, —OH, —OCH, —OCHCH, —OCHCH, —CH, —CHCH, —CHCH, cyclopropyl, fluoro, or chloro.2 is a non-hydrogen substituent in the alpha configuration. 2 is a non-hydrogen substituent in the beta configuration. 3a and R 3b and R are both hydrogen. 3a and R 3b taken together form =O (oxo). In certain embodiments, R 4 is hydrogen.
[0324] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qd): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6a The carbon attached to is in the (R) configuration. 6a is methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6ais substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6a is substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 1 is -CH3 or -CH2CH3.
[0325] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qe): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6a The carbon attached to is in the (R) configuration. 6ais methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6a is substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6a is substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, R 1 is -CH3 or -CH2CH3.
[0326] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qf): [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of R is a non-hydrogen group substituted with fluorine. 6a The carbon attached to R is in the (S) configuration. 6aThe carbon attached to is in the (R) configuration. 6a is methyl (C1) optionally substituted with one or more fluorines, e.g., —CH3 or —CF3. In certain embodiments, R 6a is substituted or unsubstituted ethyl (C2), substituted or unsubstituted n-propyl (C3), or substituted or unsubstituted isopropyl (C3). 6a is -CH2OR A6 , -CH2CH2OR A6 or -CH2CH2CH2OR A6 In certain embodiments, R 6a is substituted or unsubstituted vinyl (C2) or substituted or unsubstituted allyl (C3). In certain embodiments, R 6a is substituted or unsubstituted ethynyl (C2) or substituted or unsubstituted propargyl (C3). 6a is substituted or unsubstituted cyclopropyl. In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is —CH or —CF. In certain embodiments, R 1 is -CH3 or -CH2CH3.
[0327] In certain embodiments, the compound of formula (Iq) is: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] and pharmaceutically acceptable salts thereof.
[0328] Pharmaceutical Compositions In another embodiment, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a compound of formula (I).
[0329] When used as a pharmaceutical, the compounds provided herein are typically administered in the form of pharmaceutical compositions.Such compositions can be prepared in a manner well known in the pharmaceutical arts, and such compositions contain at least one active compound.
[0330] In one embodiment of a pharmaceutical composition, the carrier is a parenteral carrier, an oral or a topical carrier.
[0331] The present invention also relates to a compound of the present invention or a pharmaceutical composition thereof for use as a medicine or pharmaceutical.
[0332] Typically, the compounds provided herein are administered in a therapeutically effective amount. The amount of compound actually administered can typically be determined by a physician in view of the relevant circumstances, including the condition being treated, the selected route of administration, the actual compound being administered, the age, weight, and response of the individual patient, the severity of the patient's condition, etc.
[0333] The pharmaceutical compositions provided herein can be administered by various routes, including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular and intranasal.Depending on the intended delivery route, the compounds provided herein are preferably formulated as either injectable or oral compositions, or as ointments, lotions or patches (all for transdermal administration).
[0334] Compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, compositions are provided in unit dosage forms to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unit dosages for human subjects and other mammals, each unit containing a predetermined amount of active ingredient calculated to produce a desired therapeutic effect, along with suitable pharmaceutical excipients. Typical unit dosage forms include prefilled, premeasured ampoules or syringes for liquid compositions, or pills, tablets, capsules, and the like for solid compositions. In such compositions, the compound is usually a minor component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), with the remainder being various vehicles or carriers and processing aids useful in forming the desired dosage form.
[0335] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispersing agents, colorants, flavors, etc. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: binders (e.g., microcrystalline cellulose, gum tragacanth, or gelatin); excipients (e.g., starch or lactose); disintegrating agents (e.g., alginic acid, Primogel, or corn starch); lubricants (e.g., magnesium stearate); glidants (e.g., colloidal silicon dioxide); sweetening agents (e.g., sucrose or saccharin); or flavoring agents (e.g., peppermint, methyl salicylate, or orange flavor).
[0336] Injectable compositions are typically based on injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As is conventional, the active compound in such compositions is typically a minor component, often about 0.05 to 10% by weight, with the remainder being the injectable carrier and the like.
[0337] Transdermal compositions are typically formulated as topical ointments or creams containing the active ingredient in an amount generally ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, more preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredient is typically combined with a paraffinic or water-miscible ointment base. Alternatively, the active ingredient can be formulated into a cream, for example, using an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include additional ingredients that enhance skin penetration of the active ingredient or stability of the formulation. All such known transdermal formulations and ingredients are included within the scope provided herein.
[0338] The compounds provided herein can also be administered by a transdermal device. Accordingly, transdermal delivery can be accomplished using a patch either of the reservoir or porous membrane type or of a solid matrix variety.
[0339] The components described above for orally administrable, injectable, or topically administrable compositions are merely representative. Other materials, processing methods, etc. are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania (incorporated herein by reference).
[0340] The components described above for orally administrable, injectable, or topically administrable compositions are merely representative. Other materials and processing methods are set forth in Part 8 of Remington's The Science and Practice of Pharmacy, 21st edition, 2005, Publisher: Lippincott Williams & Wilkins (incorporated herein by reference).
[0341] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
[0342] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β-, and γ-cyclodextrins, each consisting of 6, 7, and 8 α-1,4-linked glucose units, optionally containing one or more substituents on the linked sugar moiety, including, but not limited to, methylated, hydroxyalkylated, acylated, and sulfoalkyl ether substituted. In certain embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, e.g., sulfobutyl ether β-cyclodextrin, also known as Captisol®. See, e.g., U.S. Patent No. 5,376,645. In certain embodiments, the formulation comprises hexapropyl-β-cyclodextrin. In more specific embodiments, the formulation comprises hexapropyl-β-cyclodextrin (10-50% in water).
[0343] The present invention also relates to pharmaceutically acceptable acid addition salts of the compounds of the present invention. The acids that can be used to prepare such pharmaceutically acceptable salts are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, para-toluenesulfonate, and the like.
[0344] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with the present invention, although the present invention is not limited to the following pharmaceutical compositions.
[0345] Exemplary Formulation 1—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active compound per tablet) in a tablet press.
[0346] Exemplary Formulation 2—Capsules: A compound of the invention can be mixed as a dry powder with a starch diluent in an approximately 1:1 weight ratio and the mixture is filled into 250 mg capsules (125 mg of active compound per capsule).
[0347] Exemplary Formulation 3 - Solution: A compound of the invention (125 mg) can be mixed with sucrose (1.75 g) and xanthan gum (4 mg), the resulting mixture can be blended and passed through a No. 10 mesh US sieve, and then mixed with a previously prepared aqueous solution of microcrystalline cellulose and sodium carboxymethylcellulose (11:89, 50 mg). Sodium benzoate (10 mg), flavor and color can be diluted with water and added with stirring. Sufficient water can then be added to bring the total volume to 5 mL.
[0348] Exemplary Formulation 4—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active compound) in a tablet press.
[0349] Exemplary Formulation 5—Injection: A compound of the invention may be dissolved or suspended in a sterile, buffered saline injectable aqueous medium to a concentration of approximately 5 mg / mL.
[0350] Exemplary Formulation 6—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 90-150 mg tablets (30-50 mg of active compound per tablet) in a tablet press.
[0351] Exemplary Formulation 7—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 30-90 mg tablets (10-30 mg of active compound per tablet) in a tablet press.
[0352] Exemplary Formulation 8—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 0.3-30 mg tablets (0.1-10 mg of active compound per tablet) in a tablet press.
[0353] Exemplary Formulation 9—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 150-240 mg tablets (50-80 mg of active compound per tablet) in a tablet press.
[0354] Exemplary Formulation 10—Tablets: A compound of the invention may be mixed as a dry powder with a dry gelatin binder in an approximately 1:2 weight ratio. A trace amount of magnesium stearate is added as a lubricant. The mixture is formed into 270-450 mg tablets (90-150 mg of active compound per tablet) in a tablet press.
[0355] Injection dose levels range from about 0.1 mg / kg / hour to at least 10 mg / kg / hour (all over about 1 to about 120 hours, particularly 24 to 96 hours). Adequate steady-state levels may also be achieved by administering a preloading bolus of about 0.1 mg / kg to about 10 mg / kg or more. The maximum total dose is expected to not exceed about 2 g / day for a 40-80 kg human patient.
[0356] For long-term prevention and / or treatment of symptoms, treatment regimens typically span months or years, and oral administration is preferred for patient convenience and tolerance. For oral administration, a typical regimen involves oral administration of 1 to 5 doses, particularly 2 to 4 doses, and typically 3 doses per day. Using these dosing patterns, each dose provides about 0.01 to about 20 mg / kg of a compound provided herein, with preferred doses providing about 0.1 to about 10 mg / kg, particularly about 1 to about 5 mg / kg, respectively.
[0357] Transdermal doses are generally selected to produce blood levels similar to or lower than those achieved with injection doses.
[0358] When used to prevent the occurrence of CNS disorders, provided herein are compounds can be administered at the dosage levels described above to subjects at risk of developing the condition, typically under the advice and supervision of a physician.Subjects at risk of developing a particular condition generally include subjects with a family history of the condition, or subjects identified by genetic testing or screening as being particularly susceptible to developing the condition. Methods of Assessment, Treatment and Use
[0359] The method for evaluating or treating patients, for example, patients with the disorders described herein, is particularly described herein.In some embodiments, the compound described herein (for example, an effective amount of the compound described herein) is administered to the patient.In some embodiments, the method includes optionally obtaining patient samples, and obtaining and / or evaluating the sample for the change in the level of 24(S)-hydroxycholesterol compared with a control. In certain embodiments, according to the evaluation, the patient is treated with the compound described herein for the disorder described herein, for example, the patient is administered an effective amount of 24(S)-hydroxycholesterol or structurally related sterol or steroid, oxysterol, NMDAR agonist or NMDAR positive allosteric modulator (PAM), a compound that enhances (for example, increases) the endogenous activity or endogenous amount of 24(S)-hydroxycholesterol (for example, a compound that inhibits the enzyme that metabolizes 24(S)-hydroxycholesterol, for example, a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)), or a compound described herein, such as a compound of formula (I).In some embodiments, the compound is an NMDAR antagonist or NAM, or a compound that reduces the endogenous activity or endogenous amount of 24(S)-hydroxycholesterol (for example, a compound that activates the enzyme that produces 24(S)-hydroxycholesterol, for example, a compound that activates cholesterol 24(S)-hydroxylase (CYP46)).
[0360] "Acquire" or "acquiring," as these terms are used herein, refers to taking ownership of a physical entity or value, e.g., a numerical value, by "directly obtaining" or "indirectly obtaining" the physical entity or value. "Directly obtaining" means obtaining a physical entity or value by performing a process (e.g., performing a synthetic or analytical method). "Indirectly obtaining" refers to receiving a physical entity or value from another party or source (e.g., a third-party laboratory that directly obtained the physical entity or value). Directly obtaining a physical entity includes performing a process that involves a physical transformation of a physical substance, e.g., a starting material. Exemplary transformations include generating a physical entity from two or more starting materials, shearing or fragmenting a material, separating or purifying a material, combining two or more separate entities into a mixture, and performing a chemical reaction that involves breaking or forming a covalent or non-covalent bond. Obtaining a value directly includes performing a process that involves a physical change of a sample or another substance, e.g., performing an analytical process that involves a physical change of a substance, e.g., a sample, analyte, or reagent (sometimes referred to herein as "physical analysis"), performing an analytical method, e.g., a method that involves one or more of the following: separating or purifying a substance, e.g., an analyte, or a fragment or other derivative thereof, from another substance; combining the analyte, or a fragment or other derivative thereof, with another substance, e.g., a buffer, solvent, or reactant; or altering the structure of the analyte, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond between a first atom and a second atom of the analyte; or altering the structure of a reagent, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond between a first atom and a second atom of the reagent.
[0361] "Obtaining a sample," as the term is used herein, refers to taking ownership of a sample, e.g., a tissue sample or a nucleic acid sample, by "directly obtaining" or "indirectly obtaining" the sample. "Directly obtaining a sample" means obtaining a sample by performing a process (e.g., performing a physical method such as surgery or extraction). "Indirectly obtaining a sample" refers to receiving a sample from another party or source (e.g., a third-party laboratory that directly obtained the sample). Directly obtaining a sample includes performing a process that involves a physical change of a physical substance, e.g., a starting material (e.g., a tissue, e.g., a tissue in a human patient or tissue previously isolated from a patient). Exemplary changes include preparing a physical entity from a starting material, dissecting or scraping tissue; separating or purifying a substance (e.g., a sample tissue or nucleic acid sample); combining two or more separate entities into a mixture; or performing a chemical reaction that involves breaking or forming a covalent or non-covalent bond. Directly obtaining a sample includes performing a process that involves a physical change of a sample or another material, e.g., as described above.
[0362] As used herein, a "candidate" patient is one who is more likely to respond to a particular therapeutic regimen than a control patient or group of patients. A "non-candidate" patient is one who is less likely to respond to a particular therapeutic regimen than a control patient or group of patients.
[0363] The compounds and pharmaceutical compositions provided herein find use as therapeutic agents for preventing and / or treating CNS conditions in mammals, including humans and non-human mammals. Accordingly, as noted above, the present invention includes and extends within its scope the recited methods of treatment, as well as compounds for such methods and the use of such compounds for the preparation of medicaments useful for such methods. In one embodiment, the compounds described herein are contemplated as therapeutic agents, for example, for treating a CNS condition in a mammal (e.g., for treating schizophrenia, depression, bipolar disorder (e.g., I and / or II), schizoaffective disorder, mood disorder, anxiety disorder, personality disorder, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive-compulsive disorder (OCD), pain (e.g., painful syndrome or disorder), sleep disorder, memory disorder (e.g., memory dysfunction), dementia, Alzheimer's disease, seizure disorder (e.g., epilepsy), traumatic brain injury (TBI), stroke, addictive disorders (e.g., addiction to opiates, cocaine, and / or alcohol), autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndrome, or tinnitus). In some embodiments, the compounds described herein can be used to improve learning (e.g., improve cognitive function) in a subject. In certain embodiments, the compounds of the present invention are useful for treating depression, anxiety, mood disorders, sleep disorders, memory disorders (e.g., memory dysfunction), traumatic brain injury, stroke, epilepsy, cognitive dysfunction, and the like. In some embodiments, the compounds described herein are useful in treating overdose, e.g., drug overdose (e.g., ketamine or PCP overdose).
[0364] Exemplary CNS conditions related to NMDA modulation include, but are not limited to, adjustment disorders, anxiety disorders (including obsessive-compulsive disorder, post-traumatic stress disorder, social phobia, generalized anxiety disorder), cognitive disorders (including Alzheimer's disease and other forms of dementia), dissociative disorders, eating disorders, mood disorders (including depression, bipolar disorder, and dysthymic disorder), schizophrenia or other psychotic disorders (including schizoaffective disorder), sleep disorders (including insomnia), substance abuse-related disorders, personality disorders (including obsessive-compulsive personality disorder), autism spectrum disorders (including those involving mutations to Shank group proteins), neurodevelopmental disorders (including Rett syndrome), pain (including acute and chronic pain), seizure disorders (including status epilepticus and monogenic forms of epilepsy, e.g., Dravet disease, and tuberous sclerosis complex (TSC)), stroke, traumatic brain injury, movement disorders (including Huntington's disease and Parkinson's disease), and tinnitus.
[0365] In another aspect, a method of evaluating or treating a mammal susceptible to or afflicted with a condition associated with brain excitability is provided, the method comprising administering an effective amount of one or more pharmaceutical compositions described herein.
[0366] In another embodiment, a method of inducing sedation or anesthesia is provided. In another embodiment, a method of evaluating or treating a mammal susceptible to or suffering from a condition associated with an adjustment disorder, an anxiety disorder, a cognitive disorder, a dissociative disorder, an eating disorder, a mood disorder, schizophrenia or other psychotic disorder, a sleep disorder, a substance-related disorder, a personality disorder, an autism spectrum disorder, a neurodevelopmental disorder, pain, a seizure disorder, a stroke, a traumatic brain injury, a movement disorder, and tinnitus is provided.
[0367] In yet another aspect, there is provided the use of a compound of the invention as a pharmaceutical, for example, particularly in the treatment or prevention of the above-mentioned conditions and diseases.
[0368] In still yet another aspect, there is provided a method for manufacturing a medicament for treating or preventing one of the above-mentioned conditions and diseases.
[0369] In still yet another aspect, the present invention provides a method for preventing, treating, ameliorating or managing a disease or condition, which method comprises administering to a subject in need of such prevention, treatment, amelioration or management a prophylactically or therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
[0370] In yet another aspect, the present invention provides the use of a compound of the present invention for the manufacture of a medicament for treating a disease or condition associated with brain excitability, in one embodiment, the disease or condition is selected from depression, anxiety, schizophrenia, sleep disorders, memory disorders, and mood disorders.
[0371] In yet another aspect, the present invention provides a method of treating a mammal, e.g., a human, for treating a disease associated with brain excitability, the method comprising treating said mammal with an effective amount of a compound of the present invention or a composition thereof.
[0372] In yet another aspect, the present invention provides a combination of a compound of the present invention with another pharmacologically active agent.
[0373] The compounds provided herein can be administered as the sole active agent or in combination with other agents. The administration in combination can proceed in any manner apparent to one skilled in the art, including, for example, separate, sequential, simultaneous, and alternating administration. [Example]
[0374] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described herein are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein, and are not to be construed as in any way limiting the scope thereof.
[0375] material and method The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. Where typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given, it will be recognized that other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimization.
[0376] Furthermore, as will be apparent to those skilled in the art, certain functional groups may require conventional protecting groups to prevent undesired reactions.The selection of suitable protecting groups for specific functional groups, as well as the selection of suitable protection and deprotection conditions, are well known in the art.For example, numerous protecting groups and their introduction and removal are described in T.W. Greene and P.G.M. Buts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and the references cited therein.
[0377] The compounds provided herein can be isolated and purified by known standard procedures. Such procedures include (but are not limited to) recrystallization, column chromatography, or HPLC. The following schemes are presented with details on the preparation of representative substituted biaryl amides listed herein. The compounds provided herein can be prepared by those skilled in the art of organic synthesis from known or commercially available starting materials and reagents.
[0378] The enantiomerically pure compounds provided herein can be prepared according to any method known to those skilled in the art. For example, they can be prepared by chiral or asymmetric synthesis from suitable optically pure precursors, or can be obtained from the racemate by any conventional method, for example, by chromatographic resolution using a chiral column, TLC, or by preparation of diastereoisomers, their separation, and regeneration of the desired enantiomer. See, for example, "Enantiomers, Racemates and Resolutions," J. Jacques, A. Collet, and S.H. Wilen, (Wiley-Interscience, New York, 1981); S.H. Wilen, A. Collet, and J. Jacques, Tetrahedron, 2725 (1977); E.L. Eliel Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and SH Wilen Tables of Resolving Agents and Optical Resolutions 268 (EL Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972, Stereochemistry of Organic Compounds, Ernest L. Eliel, Samuel H. Wilen and Lewis N. Manda (1994 John Wiley & Sons, Inc.) and Stereoselective Synthesis A Practical Approach, Miha'ly No'gra'di (1995 VCH Publishers, Inc., NY, NY).
[0379] In certain embodiments, enantiomerically pure compounds of the present invention can be obtained by reacting a racemate with a suitable optically active acid or base. Suitable acids or bases include those described in Bighley et al., 1995, "Salt Forms of Drugs and Adsorption" in Encyclopedia of Pharmaceutical Technology, vol. 13, Swarbrick & Boylan, eds., Marcel Dekker, New York; ten Hoeve & H. Wynberg, 1985, "Journal of Organic Chemistry" 50:4508-4514; Dale & Mosher, 1973, "J. Am. Chem. Soc. 95:512"; and CRC Handbook of Optical Resolution via Diastereomeric Salt Formation (the entire contents of which are incorporated herein by reference).
[0380] Enantiomerically pure compounds can also be recovered from the crystallized diastereomers or mother liquor, depending on the specific acid resolving agent used and the solubility characteristics of the specific acid enantiomer used. The identity and optical purity of the specific compound so recovered can be determined by polarimetry or other analytical methods known in the art. The diastereoisomers can then be separated, for example, by chromatography or fractional crystallization, and the desired enantiomer can be regenerated by treatment with an appropriate base or acid. The other enantiomer can be obtained from the racemate in a similar manner or can be elaborated from the initial separation. In certain embodiments, enantiomerically pure compounds can be separated from the racemate by chiral chromatography. A variety of chiral columns and eluents are available for use in separating enantiomers, and suitable conditions for separation can be determined empirically by methods known to those skilled in the art. Exemplary chiral columns available for use in the separation of enantiomers provided herein include, but are not limited to, CHIRALCEL® OB, CHIRALCEL® OB-H, CHIRALCEL® OD, CHIRALCEL® OD-H, CHIRALCEL® OF, CHIRALCEL® OG, CHIRALCEL® OJ, and CHIRALCEL® OK.
[0381] Synthesis procedure General processes for preparing compounds of the invention are provided as further embodiments of the invention and are illustrated in generalized Schemes 1-13 and Examples 1-36. For Schemes 1-13, where not defined, R' is alkyl and R 23 is R 23a or R 23b and X 1 , L 1 , R 1 , R 3a , R 3b , R 23a and R 23b is as described herein. Scheme 1. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 2. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 3. Synthesis of 3β-amino- and 3β-alkylamino steroids [ka] Scheme 4. Synthesis of steroid sulfates [ka] Scheme 5. Synthesis of steroid 3β-esters and amides [ka] Scheme 6. Synthesis of 3-oxosteroids [ka] Scheme 7. Synthesis of 21-heteroaryl-3β-hydroxysteroids [ka] Scheme 8. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 9. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 10. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 11. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 12. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 13. Synthesis of 3α-substituted-3β-hydroxysteroids [ka]
[0382] Example 1. Preparation of Compound ST-200-A-001 [ka] Preparation of compound 2: To a solution of ketone 1 (50.0 g, 0.17 mol, 1.0 eq) and ethylene glycol (62 mL) in toluene (600 mL) was added p-toluenesulfonic acid (1.4 g, 7.28 mmol). The reaction mixture was heated to reflux overnight using a Dean-Stark trap. LCMS showed that the starting material was completely consumed. The mixture was cooled to room temperature, diluted with ethyl acetate (500 mL), and washed with saturated aqueous sodium bicarbonate (300 mL × 2) and brine (300 mL × 2). The organic phase was dried over sodium sulfate and concentrated in vacuo to give crude product 2 (64.0 g, 100%), which was used directly in the next step without further purification. 1 H NMR: (400 MHz, CDCl3) δ 5.35 (d, J=5.6 Hz, 1H), 3.97-3.82 (m, 4H), 3.59-3.47 (m, 1H), 2.34-2.21(m, 2H), 2.06-1.94 (m, 2H), 1.90-1.74 (m, 3H), 1.73-1.64 (m, 1H), 1.63-1.33 (m, 10H), 1.32-1.19 (m, 1H), 1.14-1.03 (m, 1H), 1.01 (s, 3H), 0.99-0.93 (m, 1H), 0.86 (s, 3H).
[0383] Preparation of compound 3: To a solution of compound 2 (32 g, 96 mmol, 1.0 eq) in dry CHCl (1200 mL) was added Dess-Martin (81 g, 192 mmol, 2.0 eq) in portions at 0 °C. The reaction mixture was then stirred at room temperature for 3 h. TLC (PE:EA = 3:1) showed that the starting material was completely consumed. The mixture was quenched with a saturated aqueous solution of NaHCO / NaSO = 1:3 (1 L). The organic phase was washed with brine (500 mL), dried over NaSO, and the solvent was evaporated to give crude product 3 (33.0 g, 100%), which was used directly in the next step without further purification. 1H NMR: (400 MHz, CDCl3) δ 5.34 (d, J=5.2 Hz, 1H), 3.77-4.00 (m, 4H), 3.19-3.39 (m, 1H), 2.83 (dd, J=16.44, 2.13 Hz, 1H), 2.38-2.59 (m, 1H), 2.21-2.37 (m, 1H), 1.95-2.09 (m, 3H), 1.54-1.73 (m, 4H), 1.74-1.90 (m, 2H), 1.37-1.51 (m, 3H), 1.21-1.34 (m, 2H), 1.19 (s, 3H), 0.98-1.12 (m, 1H), 0.83-0.93 (m, 3H).
[0384] Preparation of MAD: To a solution of compound 5 (96 g, 436 mmol, 1.0 eq) in toluene (300 mL) was added a solution of AlMe3 (109 mL, 218 mmol, 0.5 eq, 2 M in hexane) at room temperature, at which point methane gas was immediately evolved. The resulting mixture was stirred at room temperature for 1 h and used as a solution of MAD in toluene in the next step without any purification.
[0385] Preparation of compound 4: To a solution of MAD (218 mmol, 2.3 eq, freshly prepared) in toluene (300 mL) was added a solution of compound 4 (33 g, 96 mmol, 1.0 eq) in toluene (100 mL) at −78° C. dropwise over 1 h under nitrogen. The reaction mixture was then stirred for 30 min, and a solution of MeMgBr (205 mL, 288 mmol, 3.0 eq, 1.4 M in toluene) was added dropwise at −78° C. The reaction mixture was warmed to −40° C. and stirred at this temperature for 3 h. TLC (PE:EA=3:1) showed that the starting material was completely consumed. The mixture was poured into saturated aqueous NH4Cl (200 mL) and extracted with EA (150 mL × 2). The combined organic phases were dried over Na2SO4, and the solvent was evaporated to give the crude product. The crude product was purified by silica gel chromatography eluted with PE:EA (15:1) to give the product (7.64 g, 22%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2 Hz, 1H), 3.75-4.04 (m, 4H), 2.42 (d, J=13.6 Hz, 1H), 1.88-2.12 (m, 3H), 1.73-1.86 (m, 2H), 1.64-1.72 (m, 2H), 1.52-1.63 (m, 4H), 1.35-1.51 (m, 4H), 1.19-1.32 (m, 1H), 1.12-1.18 (m, 1H), 1.10 (s, 3H), 0.99-1.03 (m, 3H), 0.92-0.98 (m, 1H), 0.86 (s, 3H).
[0386] Compound INT A: To a solution of compound 4 (6.0 g, 17.3 mmol, 1.0 eq) in THF (200 mL) was added aqueous HCl (35 mL, 1 M) and acetone (35 mL). The reaction mixture was stirred overnight at room temperature. TLC (PE:EA = 3:1) indicated that the reaction was complete. The reaction mixture was then diluted with EA (200 mL), washed with saturated aqueous NaHCO3 (200 mL), dried over Na2SO4, and evaporated under reduced pressure to give the product (5.2 g, 99.2%). 1 H NMR: (400 MHz, CDCl3) δ 5.27 (d, J=6.8 Hz, 1H), 2.45-2.35 (m, 2H), 2.09-1.84 (m, 4 H), 1.82-1.57 (m, 6H), 1.50-1.35 (m, 4H), 1.26-1.08 (m, 4H), 1.05 (s, 3H), 0.95 (s, 3H), 0.86 (s, 3H).
[0387] Compound A_001_1: To a solution of PPh3CH3Br (28.3 g, 79.35 mmol) in THF (50 mL) was added a solution of t-BuOK (8.96 g, 79.35 mmol) in THF (20 mL) at room temperature. After stirring for 1 h, INT A (4.0 g, 13.22 mmol) dissolved in THF (10 mL) was added dropwise. The reaction mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature, quenched with saturated NH4Cl, and extracted with EA. The combined organic layers were washed with brine, dried, and concentrated to give the crude product, which was purified by flash column chromatography (PE / EA=15 / 1) to give compound A_001_1 (3.2 g, Y=80%) as a white solid. 1 H NMR: (400 MHz, CDCl3) δ 5.32 (d, J=5.2 Hz, 1H), 4.65-4.64 (m, 2H), 2.50-2.42 (m, 2H), 2.27-2.22 (m, 1H), 2.07-1.97 (m, 1H), 1.87-1.68 (m, 4H), 1.68-1.49 (m, 7H), 1.40-1.15 (m, 4H), 1.12 (s, 3H), 1.05 (s, 3H), 1.04-0.96 (m, 1H), 0.80 (s, 3H).
[0388] Preparation of compound A_001_2: To a solution of compound A_001_1 (300 mg, 1.0 mmol, 1.0 eq) and methyl propiolate (250 mg, 3.0 mmol, 3.0 eq) in CHCl (5 mL) was added EtAlCl (4 mL, 4.0 mmol, 4.0 eq, 1 M in toluene) dropwise with stirring at 25 °C, and the reaction mixture was stirred overnight. TLC (PE / EA = 3 / 1) indicated that the starting material was completely consumed. The solution was washed with saturated aqueous NaHCO (5 mL), dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography eluted with PE:EA (15:1) to give the desired product (200 mg, 52%) as a white powder. 1H NMR: (400 MHz, CDCl3) δ 7.03-6.97 (m, 1H), 5.86 (dd, J1=1.2Hz, J2=15.6Hz, 1H), 5.35 (d, J=1.2Hz, 1H), 5.32 (d, J=5.2Hz, 1H), 3.72 (s, 3H), 2.87 (d, J=6.8 Hz, 2H), 2.42 (d, J=13.2 Hz, 1H), 2.13-1.95 (m, 3H), 2.00-1.40 (m, 11H), 1.40-1.20 (m, 4H), 1.11 (s, 3H), 1.06 (s, 3H), 0.90-0.82 (m, 3H), 0.78 (s, 3H).
[0389] Preparation of compound A_001_3: To a solution of compound A_001_2 (192 mg, 0.5 mmol, 1.0 eq) in EA (5 mL) was added Pd / C (5%, 40 mg) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was then stirred under a H2 balloon at 30 °C for 1 h. TLC (PE:EA = 3:1) showed the reaction was complete. The suspension was filtered through a Celite pad, and the pad was washed with EA (5 mL × 2). The combined filtrate was concentrated to dryness to give the product (185 mg, 95%) as a white powder. 1 H NMR: (400 MHz, CDCl) δ 5.31 (d, J=4.4Hz, 1H), 3.67 (s, 3H), 2.42 (d, J=13.2 Hz, 1H), 2.35-2.28 (m, 2H), 2.02-1.92 (m, 2H), 1.90-1.60 (m, 6H), 1.55-1.30 (m, 6H), 1.30-1.13 (m, 5H), 1.12 (s, 3H), 1.02(s, 3H), 1.00-0.75 (m, 4H), 0.58 (s, 3H).
[0390] Preparation of compound ST-200-A-001: To a solution of compound A_001_3 (150 mg, 0.386 mmol, 1.0 eq) in THF (5 mL), MeLi (2 mL, 3.200 mmol, 8.3 eq, 1.6 M in THF) was added dropwise under nitrogen at −78° C. After the addition, the reaction mixture was warmed to −40° C. and stirred for 1 h. TLC (PE:EA=3:1) showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NH4Cl (10 mL) and extracted with EA (10 mL × 2). The combined organic layers were concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography eluted with PE:EA (10:1) to give the product (91 mg, 60%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.31 (d, J=5.6Hz, 1H), 2.43 (d, J=13.2 Hz, 1H), 2.05-1.95 (m, 2H), 1.90-1.60 (m, 6H), 1.21 (s, 6H), 1.12 (s, 3H), 1.11-1.04 (m, 1H), 1.03 (s, 3H), 1.01-0.92 (m, 2H), 0.58 (s, 3H).
[0391] Example 2. Preparation of compound ST-200-A-003 [ka] Preparation of compound A_003_1: To a solution of Ph3PEtBr (12.25 g, 33.00 mmol, 10.0 eq) in dry THF (15 mL) was added dropwise a solution of t-BuOK (3.70 g, 33.00 mmol, 10.0 eq) in dry THF (10 mL) at 0 °C under N2. The mixture was stirred at room temperature for 1.5 h. Then, a solution of INT A (1.00 g, 3.31 mmol, 1.0 eq) in THF (10 mL) was added dropwise, and the resulting mixture was stirred at 70 °C for 4 h. TLC (PE:EA = 3:1) indicated that the starting material was completely consumed. The reaction was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EA (30 mL × 2). The combined organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluent: PE:EA=12:1) to give the product (900 mg, 90.9%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.32 (d, J=5.2Hz, 1H), 5.15-5.12 (m, 1H), 2.44-2.30 (m, 3H), 2.29-2.21 (m, 1H), 2.05-1.97 (m, 2H), 1.81-1.45 (m, 14H), 1.30-1.15 (m, 3H), 1.12 (s, 3H), 1.02 (s, 3H), 0.95-1.01 (m, 1H), 0.90 (s, 3H).
[0392] Preparation of compound A_003_2: To a solution of compound A_003_1 (1.00 g, 3.20 mmol, 1.0 eq) and methyl propiolate (0.67 g, 8.00 mmol, 2.5 eq) in dry DCM (15 mL), a solution of EtAlCl (12.8 mL, 12.8 mmol, 4.0 eq, 1 M in toluene) was added dropwise with stirring at 0 °C. The reaction was then warmed to room temperature and stirred overnight. TLC (PE:EA = 5:1) indicated that the starting material was completely consumed. The mixture was quenched with saturated aqueous NaHCO (30 mL) and extracted with DCM (30 mL × 2). The combined organic phase was dried over NaSO and concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluent: PE:EA=10:1) to give the product (1.00 g, 78.7%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 6.97-6.91 (m, 1 H) 5.82 (d, J=16 Hz, 1 H), 5.42-5.41 (m, 1H), 5.32 (d, J=5.2Hz, 1H), 3.73 (s, 3 H), 3.04-3.00 (m, 1 H), 2.43 (d, J=12.8 Hz, 1H), 2.11-1.97 (m, 3H), 1.88-1.50 (m, 12H), 1.40-1.20 (m, 3 H), 1.21-1.26 (m, 1H), 1.18 (d, J=6.78 Hz, 3H), 1.12 (s, 3H), 1.04 (s, 3H), 0.82 (s, 3H).
[0393] Preparation of compound A_003_3: To a solution of compound A_003_2 (160 mg, 0.40 mmol) in EA (15 mL) was added Pd / C (30 mg, 5%). The reaction was then stirred at room temperature under 15 psi H pressure for 2 hours. TLC (PE / EA=3 / 1) showed that the starting material was completely consumed. The reaction mixture was then filtered, and the filtrate was evaporated under reduced pressure to give the product (150 mg, 92.8%). 1H NMR: (400 MHz, CDCl3) δ 5.32 (d, J=5.2Hz, 1H), 3.67 (s, 3 H), 2.48-1.96 (m, 7H), 1.90-1.62 (m, 5H), 1.60 -1.55 (m, 7H), 1.11 (s, 3H), 1.03-0.99 (m, 3H), 0.95-0.93 (m, 2H), 0.70-0.66 (m, 2H).
[0394] Preparation of compound ST-200-A-003: To a solution of compound A_003_2 (100 mg, 0.25 mmol, 1.0 eq) in dry THF (1 mL) under N protection, MeLi (1.56 mL, 2.50 mmol, 1.6 M in THF) was added dropwise at −78° C., and the mixture was stirred at this temperature for 30 min. TLC (PE:EA=3:1) showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NH4Cl (5 mL) and extracted with EA (5 mL × 2). The combined organic layers were concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography eluted with PE:EA (10:1) to give the product (45 mg, 45%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2Hz, 1H), 2.42 (d, J=12 Hz, 1 H), 2.02-1.98 (m, 3 H), 1.92-1.66 (m, 3 H), 1.61-1.56 (m, 2 H), 1.55-1.54 (m, 2H), 1.53-1.23 (m, 11 H), 1.20 (s, 6H), 1.10 (s, 3 H), 1.05 (s, 3H), 1.02 (s, 3 H), 0.95-0.90 (m, 3 H), 0.68 (s, 3 H). Example 3. Preparation of compound ST-200-A-007 [ka]
[0395] Preparation of compound INT E: To a solution of 9-BBN (0.5 M in THF, 133 mL, 66.6 mmol, 10.0 eq) in an ice bath was added a solution of A_001_1 (2.0 g, 6.66 mmol, 1.0 eq) in THF (10 mL) dropwise. The reaction mixture was heated to 60 °C and stirred for 20 h. The mixture was cooled to 0 °C, and 10% aqueous NaOH (20 mL) was added, followed by 30% aqueous HO (30%, 10 mL). The mixture was stirred at 0 °C for 2 h and then extracted with EA (30 mL × 3). The combined organic layers were washed with brine (30 mL), dried over NaSO, and concentrated in vacuo to give the crude product, which was purified by flash column chromatography eluted with PE / EA (10 / 1) to give INT E (1.0 g, 47%) as a white solid. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2Hz, 1H), 3.75-3.71 (dd, J1=10.4Hz, J2=6.8Hz, 1H), 3.58-3.53 (dd, J1=10.4Hz, J2=7.6Hz, 1H), 2.43-2.41 (d, J=10.4Hz, 1H), 2.02-1.96 (m, 2H), 1.91 -1.75 (m, 3H), 1.72-1.44 (m, 10H), 1.33-1.20 (m, 5H), 1.18 (s, 3H), 1.06 (s, 3H), 1.04-0.99 (m, 1H), 0.67 (s, 3H).
[0396] Preparation of compound INT B: To a solution of INT E (100 mg, 0.314 mmol, 1.0 eq) in DCM (10 mL) in an ice bath, Dess-Martin reagent (265 mg, 0.628 mmol, 2.0 eq) was added. The reaction mixture was warmed to room temperature and stirred for 2 h. The mixture was poured into a solution of NaSO (4.5 g) and NaHCO (1.5 g) in water (20 mL) and extracted with EA (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over NaSO, and concentrated in vacuo to give the crude product (100 mg, 100%), which was used directly in the next step without further purification.
[0397] Preparation of compound A_007_1: A mixture of INT B (100 mg, 0.316 mmol, 1.0 eq) and Ph3P=CHCOOCH3 (634 mg, 1.89 mmol, 6.0 eq) in toluene (10 mL) was stirred at 80 °C for 3 h and then concentrated in vacuo. The residue was purified by flash column chromatography eluted with PE / EA (12 / 1) to give product A_007_1 (65 mg, 55.2%) as a white solid. 1 H NMR: (400 MHz, CDCl3) δ 6.99-6.93 (dd, J1=16 Hz, J2=8.4Hz, 1H), 5.82-5.77 (dd, J1=15.6 Hz, J2=1.2Hz, 1H), 5.30 (d, J=5.2Hz, 1H), 3.73 (s, 3H), 2.42 (d, J=12.4Hz, 1H), 2.14-2.11 (m, 1H), 2.05-1.99 (m, 2H), 1.98-1.41 (m, 15H), 1.29-1.24 (m, 2H), 1.12-1.14 (m, 1H), 1.12 (s, 3H), 1.06 (s, 3H), 1.02-0.95 (m, 1H), 0.66 (s, 3H).
[0398] Preparation of compound A_007_2: A mixture of compound A_007_1 (65 mg, 0.174 mmol, 1.0 eq) and Pd / C (5%, 20 mg) in EA (5 mL) was stirred under H2 (1 atm) at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated in vacuo to give product A_007_2 (65 mg, 100%), which was used directly in the next step without further purification.
[0399] Preparation of compound ST-200-A-007: To a solution of A_007_2 (65 mg, 0.17 mmol, 1.0 eq) in THF (2 mL) at −78° C., CH3Li (1.6 M in THF, 1 mL, 1.7 mmol, 10.0 eq) was added dropwise under nitrogen. The reaction mixture was warmed to room temperature and stirred for 1 h. The mixture was quenched with saturated aqueous NH4Cl (10 mL) and then extracted with EA (5 mL × 2). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, and concentrated in vacuo to give the crude product, which was purified by flash column chromatography (eluent: PE / EA = 8 / 1) to give ST-200-A-007 (27 mg, 41%) as a white solid. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2Hz, 1H), 2.42 (d, J=15.2 Hz, 1H), 2.02-1.96 (m, 2H), 1.86 -1.38 (m, 14H), 1.25-1.14 (m, 4H), 1.21 (s, 6H), 1.11 (s, 3H), 1.09-1.05 (m, 2H) 1.02 (s, 3H), 1.01-0.94 (m, 3H), 0.61 (s, 3H).
[0400] Example 4. Preparation of compound ST-200-A-011 [ka] Preparation of compound INT D: INT in MeOH (30 mL) and THF (15 mL) To a solution of A (2.00 g, 6.58 mmol, 1.0 eq) was added CeCl3.7H2O (2.45 g, 6.58 mmol, 1.0 eq). The reaction mixture was stirred at room temperature for 10 min. Then, NaBH4 (0.50 g, 13.16 mmol, 2.0 eq) was slowly added, and the resulting mixture was stirred at room temperature for 30 min. TLC (PE / EA = 3 / 1) showed that the reaction was complete. The reaction mixture was quenched by adding saturated aqueous NH4Cl (50 mL) and extracted with EA (50 mL × 2). The combined organic layers were dried over Na2SO4 and evaporated to dryness to give the desired product (1.84 g, 91%) as a white solid. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2 Hz, 1H), 3.65 (t, J=8.6 Hz, 1H), 2.43 (d, J=13.2 Hz, 1H), 2.09-1.97 (m, 3H), 1.97-1.68 (m, 3H), 1.64-1.38 (m, 5H), 1.31-1.20 (m, 2H), 1.19-1.16 (m, 1H), 1.11 (s, 3H), 1.11-1.04 (m, 1H), 1.03 (s, 3H), 1.01-0.93 (m, 2H), 0.88-0.84 (m, 1H), 0.76 (s, 3H).
[0401] Preparation of compound A_011_1: To a solution of INT D (500 mg, 1.63 mmol, 1.0 eq) in DCM (10 mL) were added methyl propiolate (325 mg, 3.30 mmol, 2.0 eq) and NMM (287 mg, 3.30 mmol, 2.0 eq) in sequence. The reaction mixture was stirred at room temperature for 2 days. TLC (PE / EA = 3 / 1) showed the reaction was complete. The reaction mixture was washed with saturated aqueous NaHCO3 (20 mL) and brine (20 mL), dried over Na2SO4, and evaporated to dryness to give the crude product. The residue was purified by silica gel chromatography eluted with PE:EA (15:1) to give the desired product (274 mg, 43%) as a white solid.1 H NMR: (400 MHz, CDCl3) δ 7.54 (d, J=12.8 Hz, 1H), 5. 29 (d, J=5.2 Hz, 1H), 5.24 (d, J=12.8 Hz, 1H), 3.88 (t, J=8.2 Hz, 1H), 3.68 (s, 3H), 2.42 (d, J=13.2 Hz, 1H), 2.19-2.09 (m, 1H), 2.00-1.89 (m, 2H), 1.88-1.84 (m, 1H), 1.80-1.70 (m, 2H), 1.62-1.50 (m, 5H), 1.49-1.41 (m, 2H), 1.39-1.29 (m, 1H), 1.19-1.10 (m, 2H), 1.11 (s, 3H), 1.02 (s, 3H), 1.00-0.91 (m, 2H), 0.79 (s, 3H).
[0402] Preparation of compound A_011_2: To a solution of compound A_011_1 (50 mg, 0.128 mmol) in EA (5 mL) was added 5% Pd / C (50%, 25 mg) under argon. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under a H2 balloon at room temperature for 4 h. TLC (PE / EA = 3 / 1) showed that the starting material was completely consumed. The suspension was then filtered through a Celite pad, and the pad was washed with EA (5 mL × 3). The combined filtrate was concentrated to dryness to give the product (48 mg, 96%) as a white solid, which was used directly in the next step without purification. 1H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2 Hz, 1H), 3.77-3.69 (m, 2H), 3.66 (s, 3H), 3.32 (t, J=8.4 Hz, 1H), 2.56 (t, J=6.4 Hz, 2H), 2.42 (d, J=12.4 Hz, 1H), 2.00-1.89 (m, 4H), 1.81-1.67 (m, 2H), 1.57-1.44 (m, 6H), 1.43-1.32 (m, 1H), 1.30-1.13 (m, 4H), 1.11 (s, 3H), 1.02 (s, 3H), 0.99-0.91 (m, 2H), 0.74 (s, 3H).
[0403] Preparation of compound ST-200-A-011: To a solution of compound A_011_2 (60 mg, 0.16 mmol, 1.0 eq) in anhydrous THF (5 mL) was added MeLi (1 mL, 1.60 mmol, 10.0 eq, 1.6 M in EtO) dropwise under N at −78 °C. The reaction mixture was stirred at −78 °C for 30 min and then warmed to room temperature for another 30 min. TLC (PE / EA = 3 / 1) showed that the starting material was completely consumed. The reaction mixture was quenched with saturated aqueous NH4Cl (5 mL). The resulting solution was extracted with EA (5 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography eluted with PE:EA (10:1) to give the target product (25 mg, 42%) as a white solid. 1 H NMR: (400 MHz, CDCl) δ 5.29 (d, J=4.8Hz, 1H), 3.80-3.62 (m, 2H), 3.27 (t, J=8.4 Hz, 1H), 2.39 (d, J=13.2 Hz, 1H), 2.05-1.86 (m, 4H), 1.76-1.64 (m, 3H), 1.59-1.37 (m, 8H), 1.27-1.20 (m, 1H), 1.19 (s, 6H), 1.12-1.08 (m, 2H), 1.07 (s, 3H), 0.99 (s, 3H), 0.98-0.89 (m, 2H), 0.72 (s, 3H).
[0404] Example 5. Preparation of compound ST-200-A-013 [ka] To a solution of INT E (150 mg, 0.471 mmol, 1.0 eq) in DMSO (1 mL) was added KOH (53 mg, 0.942 mmol, 2.0 eq) and 2,2-dimethyloxirane (340 mg, 4.717 mmol, 10.0 eq). The reaction mixture was stirred at 50 °C for 16 h. TLC (PE / EA = 3 / 1) showed complete consumption of the starting material. The mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), and washed with saturated aqueous NH4Cl (10 mL × 2) and water (10 mL × 2). The organic phase was dried over sodium sulfate and concentrated in vacuo to give the crude product, which was purified by column chromatography followed by prep-HPLC purification to give the pure product ST-200-A-013 (14 mg, 8%). 1 H NMR (400MHz, CDCl3) δ 5.30 (d, J=5.2Hz, 1H), 3.57-3.48 (m, 1H), 3.38-3.35 (m, 1H), 3.20 (s, 2H), 2.42-2.40 (m, 1H), 2.03-1.85 (m, 3H), 1.76 (m, 4H), 1.55-1.43 (m, 4H), 1.25 (s, 3H), 1.28-1.25 (m, 6H), 1.17-1.13 (m, 2H), 1.11 (s, 3H), 1.06-0.96 (m, 5H), 0.92-0.79 (m, 2H), 0.65 (s, 3H).
[0405] Example 6. Preparation of compound ST-200-A-017 [ka] To a solution of compound INT D (150 mg, 0.49 mmol, 1.0 eq) and 2,2-dimethyloxirane (1.5 g, 20.8 mol, 42.0 eq) in DMSO (3 mL), KOH (56 mg, 1.0 mmol, 2.0 eq) was added, and the reaction mixture was stirred at 60 °C for 5 h. TLC (PE:EA = 3:1) indicated that the reaction was complete. The solution was cooled to room temperature, diluted with water (10 mL), and extracted with EA (5 mL × 2). The combined organic layer was concentrated under reduced pressure to give the crude product, which was purified by pre-HPLC to give the product (6.6 mg, 3.5%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2Hz, 1H), 3.33 (t, J=8.0Hz, 1H), 3.29-3.22 (m, 2H), 2.40-2.50 (m, 2H), 2.05-1.85 (m, 4H), 1.82-1.65 (m, 2H), 1.60-1.35 (m, 9H), 1.34- 1.22 (m, 1H), 1.20-1.15 (m, 6H), 1.14-1.11 (m, 1H), 1.12 (s, 3H), 1.05 (s, 3H), 0.90-1.00 (m, 2H), 0.79 (s, 3H).
[0406] Example 7. Preparation of compound ST-200-A-021 [ka] To a solution of compound A_001_3 (150 mg, 0.39 mmol, 1.0 eq) in THF / HO (4 mL, 1 / 1) was added LiOH (90 mg, 2.20 mmol, 5.6 eq). The reaction was stirred at room temperature overnight. TLC (PE / EA = 3 / 1) showed that compound A_001_3 was completely consumed. The mixture was diluted with water (3 mL), washed with MTBE (5 mL × 2), and then acidified to pH = 4 with 1 M aqueous HCl. The precipitate was collected by filtration and dried in vacuo to give the product (54 mg, 37.3%). 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5.2 Hz, 2H), 2.43-2.37 (m, 1H), 2.37-2.33 (m, 2H), 2.05-1.93 (m, 2H), 1.90-1.79 (m, 2H), 1.78-1.61 (m, 6H), 1.61-1.50 (m, 6H), 1.50-1.37 (m, 3H), 1.34-1.13 (m, 4H), 1.12 (s, 3H), 1.02 (s, 3H), 0.93-1.01 (m, 3H), 0.61 (s, 3H).
[0407] Example 8. Preparation of compounds ST-200-A-022 and ST-200-A-023 [ka] Preparation of compound 7: To a solution of ketone 6 (16.7 g, 52.71 mmol, 1.0 eq) and ethylene glycol (20 mL) in toluene (450 mL) was added p-toluenesulfonic acid (418 mg, 2.20 mmol). The reaction mixture was heated to reflux overnight using a Dean-Stark trap. LCMS showed that the starting material was completely consumed. The mixture was cooled to room temperature, diluted with ethyl acetate (400 mL), and washed with saturated aqueous sodium bicarbonate (200 mL × 2) and brine (200 mL × 2). The organic phase was dried over sodium sulfate and concentrated in vacuo to give crude product 7 (19.0 g, 100%), which was used directly in the next step without further purification. 1 H NMR: (400 MHz, CDCl3) δ 5.34 (d, J=5.2 Hz, 2H), 4.00-3.85 (m, 4H), 3.53-3.51 (m, 1H), 2.28-2.22(m, 2H), 2.12-2.00 (m, 1H), 1.99-1.95 (m, 1H), 1.86-1.73 (m, 5H), 1.71-1.44 (m, 8H), 1.29 (s, 3H), 1.08 (s, 3H), 1.07 (s, 3H), 1.06-0.92 (m, 1H), 0.77 (s, 3H).
[0408] Preparation of compound 8: To a solution of compound 7 (19.0 g, 52.71 mmol, 1.0 eq) in dry CHCl (700 mL) was added Dess-Martin (45.0 g, 105.42 mmol, 2.0 eq) in portions at 0 °C. The reaction mixture was then stirred at room temperature for 3 h. TLC (PE / EA = 3 / 1) showed that the starting material was completely consumed. The mixture was quenched with a saturated aqueous solution of NaHCO / NaSO (1 L, 1 / 3). The organic phase was washed with brine (500 mL), dried over NaSO, and the solvent was evaporated under reduced pressure to give crude product 8 (19.0 g, 100%), which was used directly in the next step without further purification. 1 H NMR: (400 MHz, CDCl3) δ 5.33 (d, J=5.2 Hz, 2H), 4.01-3.85 (m, 4H), 3.34-3.21 (m, 1H), 2.82 (dd, J=16.31, 2.01 Hz, 1H), 2.59-2.40 (m, 1H), 2.37-2.25 (m, 1H), 2.13-1.95 (m, 5H), 1.87-1.41 (m, 13H), 1.30 (s, 3H), 1.21-1.15 (m, 5H), 0.81 (s, 3H).
[0409] Preparation of compound 9: To a solution of MAD (158 mL, 158 mmol, 3.0 eq, 1 M in toluene, prepared by the method described in the synthesis of ST-200-A-001), a solution of compound 8 (19.0 g, 52.71 mmol, 1.0 eq) in toluene was added under nitrogen at −78°C. The reaction mixture was then stirred at this temperature for 30 min. A solution of MeMgBr (53 mL, 159 mmol, 3.0 eq, 3 M in EtO) was added dropwise at −78°C. The reaction mixture was warmed to −40°C and stirred at this temperature for 3 h. TLC (PE:EA=3:1) showed that the starting material was completely consumed. The mixture was poured into saturated aqueous NH4Cl (300 mL) and extracted with EA (150 mL × 2). The combined organic phases were dried over Na2SO4, and the solvent was evaporated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography eluted with PE:EA (15:1) to give the product (7.70 g, 39%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.31 (d, J=5.2 Hz, 2H), 4.01-3.85 (m, 4H), 2.42 (d, J=12 Hz, 1H), 2.04-1.96 (m, 1H), 1.96-1.95 (m, 2H), 1.85-1.66 (m, 5H), 1.66-1.61 (m, 2H), 1.61 -1.36 (m, 7H), 1.33 (s, 3H), 1.26-1.13 (m, 3H), 1.11 (s, 3H), 1.05 (s, 3H), 0.91-1.00 (m, 2H), 0.80 (s, 3 H).
[0410] Preparation of compound INT C: To a solution of compound 9 (2.7 g, 7.21 mmol, 1.0 eq) in THF (20 mL), aqueous HCl (10 mL, 1 M) and acetone (10 mL) were added. The reaction mixture was stirred at room temperature overnight. TLC (PE:EA = 3:1) indicated that the reaction was complete. The reaction mixture was then diluted with EA (50 mL), washed with saturated aqueous NaHCO3 (50 mL × 2), dried over Na2SO4, and evaporated under reduced pressure to give the product (2.10 g, 88.2%) as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.31 (d, J=5.2 Hz, 2H), 2.55-2.50 (m, 1H), 2.40 (d, J=12Hz, 1H), 2.20 -2.19 (m, 1H), 2.15-2.10 (m, 3H), 2.08-1.94 (m, 3H), 1.83-1.76 (m, 1H), 1.74 -1.65 (m, 3H), 1.62 (s, 3H), 1.61-1.39 (m, 7H), 1.30-1.13 (m, 4H), 1.12 (s, 3H), 1.01 (s, 3H), 0.61-0.65 (m, 3H).
[0411] Preparation of compound A_022_1: To a solution of INT C (700 mg, 2.1 mmol, 1.0 eq) in MeOH (10 mL) and THF (5 mL) was added NaBH4 (160 mg, 4.2 mmol, 2.0 eq) in five portions. The reaction mixture was stirred at room temperature for 1 h. TLC (PE / EA=3 / 1) showed that the starting material was completely consumed. The mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EA (20 mL × 2). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, and concentrated in vacuo to give the desired product A_022_1 (600 mg, 86%).
[0412] Preparation of compounds ST-200-A-022 and ST-200-A-023: To a solution of A_022_1 (570 mmol, 1.717 mmol, 1.0 eq) in DCM (15 mL) was added TEA (867 mg, 8.585 mmol, 5.0 eq) and DMAP (63 mg, 0.515 mmol, 0.3 eq). BzCl (961 mg, 6.867 mmol, 4.0 eq) was then added dropwise. The resulting mixture was stirred at room temperature for 16 hours and then neutralized by adding 1 M aqueous HCl. The aqueous layer was separated and extracted with DCM (10 mL × 3). The combined organic layers were washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluted with PE:EA (15:1) to give the product (360 mg, 46.6%) as a white solid, which was subjected to SFC separation to give the target ST-200-A-022 (100 mg) and ST-200-A-023 (70 mg). 1 H NMR(ST-200-A-022): (400 MHz, CDCl3) δ 8.06 (d, J=7.2 Hz, 2H), 7.61-7.50 (m, 1H), 7.49-7.40 (m, 2H), 5.30 (d, J=5.2 Hz, 2H), 5.19-5.08 (m, 1H), 2.40 (d, J=12Hz, 1H), 2.03-1.86 (m, 3H), 1.85-1.64 (m, 5H), 1.58-1.30 (m, 7H), 1.27 (d, J=6.0 Hz, 3H), 1.23-1.06 (m, 6H), 1.01-0.83 (m, 5H), 0.68 (s, 3H). 1 H NMR(ST-200-A-023): (400 MHz, CDCl3) δ 8.01 (d, J=8.4Hz, 2H), 7.58-7.50 (m, 1H), 7.47-7.39 (m, 2H), 5.31 (d, J=6.0 Hz, 2H), 5.24-5.14 (m, 1H), 2.43 (d, J=13.2Hz, 1H), 2.05-1.87 (m, 4H), 1.82-1.61 (m, 5H), 1.55-1.38 (m, 4H), 1.36 (d, J=6.0 Hz, 3H), 1.29-1.14 (m, 4H), 1.12 (s, 3H), 1.04-0.95 (m, 4H), 0.74 (s, 3H).
[0413] Example 9. Preparation of compound ST-200-C-001 [ka] To a solution of compound ST-200-A-001 (65 mg, 0.167 mmol, 1.0 eq) in ethanol (10 mL) was added Pd / C (10%, 15 mg) under N. The suspension was degassed under vacuum and purged with H several times. The mixture was then stirred at 60 °C under 50 psi hydrogen pressure for 24 h. TLC (PE:EA = 3:1) showed that the reaction w...
Claims
[Claim 1] The method described in the specification.
